Quaternary Pyridinium Compounds And Uses Therefor by Powers, James C. et al.
United States Patent [I9J 
Powers et al. 
[54] QUATERNARY PYRIDINIUM COMPOUNDS 
AND USES THEREFOR 
[75] Inventors: James C. Powers; Sheldon W. May, 
both of Atlanta; Maria A.Hernandez, 
Norcross, all of Ga.; Steve Thornton, 
Raleigh, N.C.; Jan Glinski, New 
Fairfield, Conn. 
[73] Assignee: Georgia Tech Research Corporation, 
Atlanta, Ga. 
[21] Appl. No.: 6,367 
[22) Filed: Jan. 19,1993 
[62] 
Related U.S. Application Data 
Division of Ser. No. 565,520, Aug. 10, 1990, Pat. No. 
5,180,831, Division of Ser. No. 892,222, Jun. 2, 1992, 
Pat. No. 5,206,371. 
[51) Int. a.s ............................................ C07D 213/53 
[52] U.S. Cl ...................................... 546/300; 546/338 
[58) Field of Search ................................ 546/300, 338 
[56) References Cited 
PUBLICATIONS 
CA 55:11507i (Jun. 1961). 
Primary Examiner-C. Warren Ivy 
Assistant Examiner-Phyllis G. Spivack 
Attorney, Agent, or Firm-Deveau, Colton & Marquis 
[57) ABSTRACT 
Quaternary pyridinium compounds for use as acetyl-
cholinesterase inhibitors of the following formulas: 
xn DX I and I 
~ ~ 
N CH=NOR1 B N CH=NOR1 
I+ I+ 
z z 
111111 llllllll Ill lllll lllll lllll lllll lllll lllil 1111111111111111111111111111 
US005290942A 
[I I] Patent Number: 5,290,942 
[45] Date of Patent: Mar. 1, 1994 
-continued xn 1 y and ~ II 
N CH=NNH-C-NR2R3 
I 
z+ 
~x 
~ ,l_ fl 
B N CH=NNH-C-NR2R3 
I+ 
z 
ll N CH=NOR9 ll fi N CH=NNH-C-NR7Rg 
I+ 
z 
I+ 
z 
X1~ 
l .l fi N CH=NNH-C-1l4 and 
I+ 
z 
~X1 
~ ,l_ fi 
B N CH=NNH-C-R4 
I 
z+ 
,erx 
B N CH=NNRsR6 
I+ 
z 
(Abstract continued on next page.) 
-continued 
x~ 
l l f CH= NOH 
z+ 
.and 
5,290,942 
Page 2 
3 Cl. auns, No Drawings 
1 
5,290,942 
2 
QUATERNARY PYRIDINIUM COMPOUNDS AND 
USES THEREFOR 
nucleophiles which are required to dephosphonylate 
the enzyme. 
Other approaches to OP antidotes have dealt with 
changes in the heteroaromatic ring system in order to 
ST A TEMENT OF GOVERNMENT INTEREST 
This invention was made with Government support 
under Contract No. DAMD17-85-C-5143 awarded by 
the U.S. Army Medical Research and Development 
Command. The Government has certain rights in the 
invention. 
5 improve the reactivation of OP-inhibited acetylcholin-
esterase (Bedford, C. D., Harris, R. N., III, Howd, R. 
A., Goff, D. A., Koolpe, G. A., Petesch, M., Koplovitz, 
I., Sultan, W. E., and Musallam, H. A., J. Med. Chem. 
1989, 32, 504; Bedford, C. D., Harris, R. N., Howd, R. 
10 A., Goff, D. A., Koolpe, G. A., Petesch, M., Miller, A., 
Nolen, H. W., III, Musallam, H. A., Pick, R. 0., Jones, 
D. E., Koplovitz, I., and Sultan, W. E., J. Med. Chem. 
1989, 32, 493; Benschop, H. P., Van der Berg, G. R., 
This is a divisional of co-pending applications Ser. 
No. 07/565,520 filed on Aug. 10, 1990 now U.S. Pat. 
No. 5,180,831 and Ser. No. 07/892,222, filed on Jun. 2, 
1992 now U.S. Pat. No. 5,206,371. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
i 5 Van der Hooidonk, C., DeJong, L. P.A., Kientz, C. E., Berends, F., Kepner, L. A., Meeter, E., and Visser, R. 
P. L. S., J. Med. Chem. 1979, 22, 1306; Grifantini, M., 
Martelli, S., and Stein, M. L., J. Med. Chem. 1973, 16, 
937, incorporated herein by reference). This invention relates to a novel class of quaternary 
pyridinium compounds useful for selectively inhibiting 
acetylcholinesterase (AChE) and to their use as nerve 20 
agent antidotes and prophylactics. We have found that 
certain quaternary pyridinium derivatives can offer in 
vivo protection against the nerve agents Soman (GD) 
and Tabun (GA) and therefore they can also offer pro-
tection against other organophophate poisons. We have 25 
also found that certain quaternary pyridinium deriva-
tives can effectively increase the rate of survival of 
experimental animals exposed to the nerve agents GD 
and GA and therefore they can also serve as antidotes 
against other organophosphate poisons. All of the ac- 30 
tive pyridinium compounds are good AChE inhibitors 
in vitro and therefore they can also be used to treat 
conditions where a cholinergic deficit leading to pathol-
ogy can be ameliorated by administration of an anticho-
linesterase agent. All of the pyridinium compounds 35 
described herein can have additional beneficial effects 
in living organisms by virtue of their resemblance to the 
natural neurotransmitter acetylcholine and their ability 
to act on cholinergic receptors. 
2. Description of the Related Art 40 
Development of an effective antidote to organophos-
phorus (OP) nerve agents has been a goal of medicinal 
chemists since the development of Tabun in Germany 
in 1937. OP agents react covalently with the active site 
serine hydroxyl group of acetylcholinesterase (AChE) 45 
to form a stable phosphonyl ester which requires up to 
30 days for hydrolysis (Main, A. R. In Biology o/Cholin-
ergic Function; Goldberg, A. M., Hanin, I., Eds.; Raven 
Press: New York, 1976; pp. 269-353, incorporated 
herein by reference). Excess acetylcholine accumulates so 
and causes severe neurological imbalance, respiratory 
paralysis, and death (Koelle, G. G. In The Phannacolog-
ical Basis of Therapeutics; Goodman, L., and Gilman, A., 
Eds.; MacMillan: New York, 1975; p. 404, incorporated 
herein by reference). Pyridinium aldoximes (2-PAM SS 
and Hl-6, see structures below) are currently used in 
conjunction with an acetylcholine antagonist (atropine) 
to reactivate the phosphonylated serine hydroxyl group 
of AChE after poisoning occurs (Leadbeater, L., Inns, 
R. H., and Rylands, J. M. Fund. App. Toxicol. 1985, 5, 60 
S225, incorporated herein by reference). This treatment 
is ineffective against GD and GA because the initially 
formed enzyme bound alkyl phosphonate esters un-
dergo rapid aging with loss of the alkoxy side chain to 
form a negatively charged phosphonyl mono ester 65 
(Wolthuis, 0. L., Berends, F., and Meeter, E., Fund. 
Appl. Toxicol. 1981, l, 183, incorporated herein by refer-
ence). The negative charge on this mono ester repels 
ll 
+N CH=NOH 
I 
CH3 
2-PAM Chloride 
HI-6 
Since it is difficult to reactivate aged phosphonylated 
AChE, prophylactic treatment with AChE inhibitors 
may be the preferred alternative. AChE is protected 
from nerve agents by preadministration of an AChE 
carbamylating agent such as pyridostigmine or physo-
stigmine. These carbamates react covalently with 
AChE at the active site serine, but the carbamylated 
enzyme is hydrolyzed quickly to active enzyme (30 
min.) while phosphonylated AChE requires several 
hours or days for regeneration of active AChE (Main, 
A. R., vide supra). Blocking AChE for a short period of 
time allows destruction of the OP agent by uncatalyzed 
hydrolysis or reaction with enzymes such as carboxyles-
terase or pseudocholinesterase (Harris, L. W., Stitcher, 
D. L., and Heyl, W. C., Life Sci. 1980, 26, 1885, incorpo-
rated herein by reference). Unfortunately, physostig-
mine is very toxic and small doses can be lethal. Fur-
thermore, physostigmine is unstable and would rapidly 
decompose in the battlefield. Both carbamates are effec-
tive only when combined with several other drugs 
(Heyl, W. C., Harris, L. W., and Stitcher, D. L., Drug 
Chem. Toxicol. 1980, 3, 319, incorporated herein by 
reference). 
Other approaches to prophylaxis against OP poison-
ing have involved the use of cyclic organophosphates to 
temporarily block AChE (Ashani, Y., Leader, H., 
Raveh, L., Bruckstein, R. and Spiegelstein, M., J. Med. 
Chem. 1983, 26, 145, incorporated herein by reference), 
reduction of AChE levels by inhibition of choline ace-
tyl transferase (Gray, A. P., Platz, R. D., Henderson, T. 
R., Chang, T. C. P., Takahashi, K. and Dretchen, K. L., 
J. Med. Chem. 1988, 31, 807, incorporated herein by 
3 
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reference), and the use of antimuscarinic a-adrenergic 
agonists (e.g., clonidine) to block the release of acetyl-
choline from presynaptic nerve terminals (Buccafusco, 
J. J. and Aronstam, R. S., J. Pharmacol. Exp. Ther. 1986, 
239, 43, incorporated herein by reference). 5 
Many oxime, semicarbazone, hydrazone and acyl 
hydrazone derivatives of 2-formyl-3-hydroxy-l-methyl-
pyridinium chloride described herein incorporate both, 
a nucleophile to displace the phosphonate from the 
serine hydroxyl group of AChE and an additional by- 10 
drogen bonding group (hydroxyl) to neutralize the neg-
ative charge on the aged phosphonate mono ester. In 
addition, the parent 3-hydroxypyridinium derivatives 
were converted into various carbamates since these are 
pyridostigmine analogs and can react covalently with 15 
AChE and thus provide protection from OP agents. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Aldoxime, hydrazone, semicarbazone and acyl by- 20 
drazone derivatives of 2-formyl-1-substituted pyridin-
ium compounds are good inhibitors of acetylcholines-
terase (AChE) and can displace a nerve agent from the 
enzyme active site or protect the latter from attack by a 
nerve agent. Therefore these structures can be used as 25 
antidotes and prophylactics against nerve agents or 
other organophosphate poisons. Furthermore, it is pos-
sible that the carbamates act first as prophylactics 
against OP poisoning and that the reaction products 
(3-hydroxy derivatives) act as reactivators of phos- 30 phonylated AChE (see below). Herein we describe one 
instance of this prophylactic/prodrug concept. 
(J(
OCONR"R"' 
AChE > 
"' +N CH= Nu 
I 
R' 
Nu = nucleophile 
Prophylactic 
(J(OH 
+N CH=Nu 
I 
R' 
Reactivator 
35 
40 
In addition to their AChE inhibitory properties, these 
derivatives can act on cholinergic receptors in the ner-
vous system either to mimic or to oppose the effects of 
the natural neurotransmitter acetylcholine. Therefore 45 
these structures can also be used in the treatment of 
conditions such as Myasthenia Gravis, Alzheimer's 
disease and adult Down's syndrome where a choliner-
gic deficit leading to pathology can be ameliorated by 
administration of a cholinomimetic or an anticholines- 50 
terase agent. These structures can also act on the cardi-
ovascular system to produce an antihypertensive effect; 
they can be useful in the treatment of glaucoma; they 
can enhance bowel tone and motility. 
The novel substituted pyridinium derivatives have SS 
the following structural formulas: 
with an attached naphtyl group, C1.6(llkyl with two 
attached phenyl groups, C1.6(llkyl with an attached 
phenyl group mono, di, or trisubstituted with J, 
C1.6(llkyl with two attached phenyl groups mono, 
di, or trisubstituted with J, C1.6(llkyl with an at-
tached naphtyl group mono, di, or trisubstituted 
with J, 
wherein J is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1.6<llkyl, 
C1-6<llkoxy, C1-6<llkylamine, C1-6<llkyl-O-CO-, 
C1-6lllkyl-O-CO-NH-, C1.6(l]kyl-N-
H-CO-NH-, C1.6(l]kyl-NH-CO-O-, C1. 
6alkyl NH-CO-, (C1.6(llkyl)2N-CO-, 
wherein X is selected from the group consisting of 
OH, C1.6<llkyl-NH-CO-O-, (C1-6<llkyl)-
2-N-CO-O-, C1-6fluoroalkyl-N-
H-CO-O-, (C1-6fluoroalkyl-NH-CO-O-, 
(C1-6fluoroalkyl)2-NH-CO-O-, 
wherein R1 is selected from the group consisting of 
C1.6(llkyl, C1-6<llkyl with an attached phenyl group, 
C1.6(llkyl with two attached phenyl groups, C1.6(ll-
kyl with an attached phenyl group mono, di, or 
trisubstituted with K, C1.6(l]kyl with two attached 
phenyl groups mono, di, or trisubstituted with K, 
C1-6<llkyl with an attached naphtyl group, C1.6(llkyl 
with an attached naphtyl group mono, di, or trisub-
stituted with K, C1.6(llkyl-T, 
wherein T is selected from the group consisting of 
formula (I) and formula (II), 
R' 
I 
-N+-R" 
I 
R'" 
Formula I 
Formula II 
wherein R', R", and R'" are selected from the group 
consisting of H, C1-6<llkyl, C1-6fluoroalkyl, C1-6<ll-
kyl with an attached phenyl group, C1.6(l]kyl with 
an attached phenyl group mono, di, or trisubstitu-
ted with K, C1.6fluoroalkyl with an attached 
phenyl group mono, di, or trisubstituted with K, 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1.6(llkyl, 
C1~lkoxy, C1~lkylamine, C1.6(l]kyl-O-CO-, 
C1~lkyl-O-CO-NH-, C1.6(l]kyl.,.-N-
H-CO-NH-, C1-6<llkyl-NH-CO-O-, C1. 
6alkyl NH-CO-, (C1.6(llkyl)2N-CO-, 
wherein B is selected from the group consisting of H, 
C1-6<llkyl. 
Xn· -?" lJCX I and I Alternatively the novel quaternary pyridinium com-pounds are represented by the following structural for-60 mulas: 
"' "' N CH=NOR1 B N CH=NOR1 
I+ I+ 
z z 
with any counterion to make pharmaceutically accept- 65 
able salts, wherein 
Z is selected from the group consisting of C1.6(llkyl, 
C1-6<llkyl with an attached phenyl group, C1.6<llkyl 
5 
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5 
with any counterion to make pharmaceutically accept-
10 able salts, wherein 
Y is 0 or S, 
wherein Ri is selected from the group consisting of 
H, C1-6lllkyl, phenyl, C1-6lllkyl with an attached 
phenyl group, C1-6lllkyl with an attached phenyl 15 
group mono, di, or trisubstituted with K, C1-6lllkyl 
with an attached naphtyl group, C1-6lllkyl with an 
attached naphtyl group mono, di, or trisubstituted 
w~~ W 
wherein R3 is selected from the group consisting of 
H, C1-6lllkyl, phenyl, C1-6lllkyl with an attached 
phenyl group, C1-6lllkyl with an attached phenyl 
group mono, di, or trisubstituted with K. 
Alternatively the novel quaternary pyridinium com- 25 
pounds are represented by the following structural for-
mulas: 
X1~ 
l ~ fl 
N CH=NNH-C-R.i and 
I+ 
30 
z 
35 
~X1 
6 
-continued 
Formula II 
wherein R', R", and R"' are selected from the group 
consisting of H, C1-6 alkyl, C1-6 fluoroalkyl, C1-6 
alkyl with an attached phenyl group, C1-6 alkyl 
with an attached phenyl group mono, di, or trisub-
stituted with K, C1-6 fluoroalkyl with an attached 
phenyl group mono, di, or trisubstituted with K, 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, 
C1-6 alkoxy, C1-6 alkylamine, C1-6 al-
kyl-0-CO-, C1-6 alkyl-0-CO-NH-, C1-6 
alkyl-NH-CO-NH-, C1-6 alkyl-N-
H-C0-0-, C1-6 alkyl NH-CO-, (C1-6 alkyl)-
2N-CO-. 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for-
mulas: . 
lJ(x 
B . N+ CH=NNRsR6 
I 
z 
~ ,!._ fl 
B N CH=NNH-C-R.i 
I+ 
z 
with any counterion to make pharmaceutically accept-
40 able salts, wherein 
with any counterion to make pharmaceutically accept· 
able salts, wherein 
X1 is selected from the group consisting of H, OH, 45 
Ci-6 alkyl-NH-C0-0-, (C1-6 alkyl)-
2-N-CO-O-, C1-6 fluoroalkyl-N-
H-C0-0-, (C1-6 fluoroalkyl)i-N-
H-C0-0-, 50 
wherein ~ is selected from the group consisting of 
C1-6 alkyl with a pyridinium ring attached through 
nitrogen, C1-6alkyl with a pyridinium ring attached 
through nitrogen and mono, di, or trisubstituted 
with K, C1-6alkyl with a quinolinium ring attached 55 
through nitrogen and mono, di, or trisubstituted 
with K, C1-6 alkyl with an isoquinolinium ring at-
tached through nitrogen and mono, di, or trisubsti-
tuted with K, C1-6 alkyl-T, 60 
wherein T is selected from the group consisting of 
formula (I) and formula (II), 
Rs is selected from the group consisting of C1-6 alkyl, 
phenyl, C1-6 alkyl with an attached phenyl group, 
C1-6 alkyl with an attached phenyl group mono, di, 
or trisubstituted with K, C1-6alkyl with an attached 
naphtyl group, C1-6 alkyl with an attached naphtyl 
group mono, di, or trisubstituted with K, 
wherein R6 is selected from the group consisting of 
H, C1-6 alkyl, phenyl, C1-6 alkyl with an attached 
phenyl group, C1-6 alkyl with an attached phenyl 
group mono, di, or trisubstituted with K. 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for-
mulas: 
R' 
I 
Formula I 
with any counterion to make pharmaceutically accept-
65 able salts. 
-N+-R" 
I 
R"' 
Alternatively the novel quaternary pyridinium com-
pounds are represented by the following structural for-
mula: 
7 
(l fi 
N+ CH=NNH-C-NR7Rs 
I 
z 
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0-(2-Methyl- l-naphtylmethyl)-N-(3-hydroxy- l-meth-
yl-2-pyridinemethylene) hydroxylamine chloride. 
0-(2,3,4-Trimethoxybenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
5 0-(3,3-Diphenylpropyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
0-(1-Naphtylmethyl)-N-(1,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylamine chloride. 
with any counterion to make pharmaceutically accept- 0-(2-Methyl-1-naphtylmethyl)-N-(1,6-dimethyl-3-
able salts, wherein 10 hydroxy-2-pyridinemethylene) hydroxylamine chlo-
R 7 is selected from the group consisting of C1-6 alkyl, ride. 
phenyl, C1-6 alkyl with an attached phenyl group, O-Methyl-N-(3-hydroxy-l-methyl-2-pyridinemethy-
C1-6alkyl with an attached phenyl group mono, di, Iene) hydroxylamine chloride (le). 
or trisubstituted with K, C1-6alkyl with an attached O-Methyl-N-(l,6-dimethyl-3-hydroxy-2-
naphtyl group, C1.6 alkyl with an attached naphtyl 15 pyridinemethylene) hydroxylamine chloride. 
group mono, di, or trisubstituted with K, 0-[2-(l-Methyl-l-piperidinium]ethyl]-N-(3-hydroxy-l-
-CO-C1.6 alkyl, -CO-C1-6 alkyl with an at- methyl-2-pyridinemethylene) hydroxylamine dichlo-
tached phenyl group mono, di, or trisubstituted ride. 
with K, 20 0-[2-(Trimethylammonium)ethyl]-N-(3-hydroxy-l-
wherein Rs is selected from the group consisting of methyl-2-pyridinemethylene) hydroxylamine dichlo-
H, C1-6 alkyl, phenyl, C1.6 alkyl with an attached ride. 
phenyl group, C1-6 alkyl with an attached phenyl O-(p-Chlorobenzyl)-N-(3-hydroxy-l-methyl-2-
group mono, di, or trisubstituted with K. pyridinemethylene) hydroxylamine chloride (Id). 
Alternatively the novel quaternary pyridinium com- 25 O-(p-Cyanobenzyl)-N-(3-hydroxy-1-methyl-2-
pounds are represented by the following structural for- pyridinemethylene) hydroxylamine chloride. 
mula: 0-(2-Hydroxy-4-nitrobenzyl)-N-(3-hydroxy- l-methyl-
(l 
N+ CH=NOR9 
I 
z 
2-pyridinemethylene) hydroxylamine chloride. 
O-(p-Carboxybenzyl)-N-(3-hydroxy- l-methyl-2-
30 pyridinemethylene) hydroxylamine chloride. 
O-(p-Chlorobenzyl)-N-(l,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylamine chloride. 
O-(p-Cyanobenzyl)-N-(l,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydroxylamine chloride. 
35 0-(2-Hydroxy-4-nitrobenzyl)-N-( l ,6-dimethyl-3-
with any counterion to make pharmaceutically accept- hydroxy-2-pyridinemethylene) hydroxylamine chlo-
able salts, wherein ride. 
R9 is selected from the group consisting of C1.6 alkyl O-(p-Methoxybenzyl)-N-(3-hydroxy-l-methyl-2-
with an attached phenyl group, C1-6alkyl with two pyridinemethylene) hydroxylamine chloride (le). 
attached phenyl groups, C1-6alkyl with an attached 40 0-(p-Dimethylaminocarbonyloxy benzyl)-N-(3-
phenyl group mono, di, or trisubstituted with K, hydroxy-l-methyl-2-pyridinemethylene) ·hydroxy-
C1-6 alkyl with two attached phenyl groups mono, !amine chloride. 
di, or trisubstituted with K, C1-6 alkyl with an at- 0-(p-Propylaminocarbonyl benzyl)-N-(3-hydroxy-l-
tached naphtyl group, C1-6 alkyl with an attached methyl-2-pyridinemethylene) hydroxylamine chlo-
naphtyl group mono, di, or trisubstituted with K. 45 ride. 
The following compounds are representative of the 0-(p-Ethoxycarbonyl benzyl)-N-(3-hydroxy-l-methyl-
invention: 2-pyridinemethylene) hydroxylamine chloride. 
O-Benzyl-N-(l-methyl-2-pyridinemethylene) hydroxy- O-(p-Methoxybenzyl)-N-(l,6-dimethyl-3-hydroxy-2-
lamine chloride (la). 50 pyridinemethylene) hydroxylamine chloride. 0-(Diphenylmethy 1)-N-( l-methyl-2-pyridinemethy- 0-(p-Dimethylaminocarbonyloxy benzyl)-N-( 1,6-
lene) hydroxylamine chloride. dimethyl-3-hydroxy-2-pyridinemethylene) hydroxy-
0-(p-Chlorobenzyl)-N-(l-methyl-2-pyridinemethylene) !amine chloride. 
hydroxylamine chloride. 0-(p-Propylaminocarbonyl benzyl)-N-(1,6-dimethyl-3-
0-(p-Methoxybenzyl)-N-(1-methyl-2-pyridinemethy- 55 hydroxy-2-pyridinemethylene) hydroxylamine chlo-
lene) hydroxylamine chloride. ride. 
0-( 1-Naphtylmethy 1)-N-( l-methyl-2-pyridinemethy- 0-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy-1-
lene) hydroxylamine chloride. methyl-2-pyridinemethylene] hydroxylamine chlo-
0-(2-Methyl-l-naphtylmethyl)-N-( l-methyl-2- ride (2a). 
pyridinemethylene) hydroxylamine chloride. 60 0-[2-(l-Methyl-1-piperidinium)ethyl)-N-[3-(N',N' -
0-(2,3,4-Trimethoxybenzyl)-N-( l-methyl-2- dimethylcarbamoyl)hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride. pyridinemethylene] hydroxylamine dichloride. 
0-{3,3-Diphenylpropyl)-N-(1-methyl-2-pyridinemethy- 0-[2-(Trimethylammonium)ethyl)-N-[3-(N',N'-dime-
lene) hydroxylamine chloride. thylcarbamoyl)hydroxy-1-methyl-2-pyridinemethy-
O-Benzyl-N-(3-hydroxy-1-methyl-2-pyridinemethy- 65 Jene] hydroxylamine dichloride. 
Jene) hydroxylamine chloride (lb). O-Benzyl-N-[3-(N',N'-diethylcarbamoyl)hydroxy-1-
0-(1-Naphtylmethyl)-N-(3-hydroxy-1-methyl-2- methyl-2-pyridinemethylene] hydroxylamine chlo-
pyridinemethylene) hydroxylamine chloride. ride. 
5,290,942 
9 10 
0-Benzyl-N-[3-(N',N'-difluoroethylcarbamoyl)hy- N-[5-(N',N'-Dimethylcarbamoyl)hydroxy-1-methyl-2-
droxy-1-methyl-2-pyridinemethylene] hydroxylam- pyridinemethylene] hydroxylamine chloride (2d). 
ine chloride. N-[3-(N' ,N' -Dimethylcarbamoyl)hydroxy-1-methyl-2-
0-Diphenylmethyl-N-(3-hydroxy-1-methyl-2- pyridinemethylene] hydroxylamine chloride. 
pyridinemethylene) hydroxylamine iodide. 5 N-[3-(N' ,N' -Dimethylcarbamoyl)hydroxy-1,6-dimeth-
O-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy- yl~2-pyridinemethylene] hydroxylamine chloride. 
1,6-dimethyl-2-pyridinemethy Jene] hydroxylamine 0-( 1-Naphtylmethyl)-N-( 5-hydroxy-1-methyl-2-
chloride. pyridinemethylene) hydroxylamine chloride. 
0-Benzyl-N-[3-(N' ,N' -diethylcarbamoyl)hydroxy-1,6- 0-(2-Methyl-1-naphtylmethyl)-N-( 5-hydroxy-1-meth-
dimethyl-2-pyridinemethylene] hydroxylamine chlo- 10 yl-2-pyridinemethylene) hydroxylamine chloride. 
ride. 0-(2,3,4-Trimethoxybenzyl)-N-(5-hydroxy-1-methyl-2-
0-Benzyl-N-[3-(N',N' -difluoroethylcarbamoyl)hy- pyridinemethylene) hydroxylamine chloride. 
droxy-1,6-dimethyl-2-pyridinemethylene] hydroxy- 0-(3,3-Diphenylpropyl)-N-(5-hydroxy-1-methyl-2-
lamine chloride. pyridinemethylene) hydroxylamine chloride. 
0-{Diphenylmethyl)-N-[3-(N',N'-dimethylcarbamoyl)- 15 O-Methyl-N-(5-hydroxy-1-methyl-2-pyridinemethy-
hydroxy-I-methyl-2-pyridinemethylene] hydroxy- Jene) hydroxylamine chloride. 
Iamine chloride (2b). O-(p-Chlorobenzyl)-N-(5-hydroxy-l-methyl-2-
0-{Diphenylmethyl)-N-~3~(N' -isopropylcarbamoyl)hy- pyridinemethylene) hydroxylamine chloride. 
?roxy-1-~ethyl-2-pyndmemethylene] hydroxylam- O-(p-Cyanobenzyl)-N-(5-hydroxy-1-methyl-2-
me chlonde. 20 ·d· h 1 ) h d I · hi ·d o (D' h I th I) N [3 [N' (2 fl h I) pyn memet y ene y roxy amme c on e. 
-b lp eln]hy md e Y 1- ·th- 1 2- - ~d~roet Yb c1ar-] h 0-(2-Hydroxy-4-nitro benzyl)-N-(5-hydroxy-1-methyl-amoy y roxy- -me y - -pyn memet y ene y- 2 . . . . droxylamine chloride. -pyndmemethylene) hydroxylamme chlonde. 
0-(Di henylmeth 1)-N-[3-(N' N'-dimeth lcarbamo I)- 0-(p-<?~rboxy benzyl)-N-(5-~ydroxy-.1-methyl-2-
h P . Y '. . Y Y pyndmemethylene) hydroxylamme chlonde. ydroxy-l,6-d1methyl-2-pyndmemethylene] hydrox- 25 0 (p M h b I) N (5 h d 1 h 1 2 ylamine chloride. - - . d ~t ox\ e~zy )-h - - Y lrox.y- -mhel t .Y - -
O-(Diphenylmethyl)-N-[l,6-dimethyl-3-(N'-isopropyl- pyn .memet Y :ne ydroxy amme c onde. 
carbamoyl)hydroxy-2-pyridinemethylene] hydroxy- O-(p-D1methylammocarbo~~Ioxy . benzyl)-N-(5-
Iamine chloride hydroxy-l-methyl-2-pyndmemethylene) hydroxy-
0-(Diphenylmeth~l)-N-[3-[N' -(2-fluoroethyl)car- 30 !amine chlori.de. 
bamoyl]hydroxy-1,6-dimethyl-2-pyridinemethylene] 0-(p-Propylam~n?carbonyl benzyl)-N-(5-h~droxy-1-
hydroxylamine chloride. ~ethyl-2-pyndmemethylene) hydroxylamme chlo-
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- nde. 
bamoyl)hydroxy-1-methyl-2-pyridinemethylene] by- 0-(p-Et~~xycarbonyl benzyl)-N-(5-~ydroxy-.1-methyl-
droxylamine chloride (2c). 35 2-pyndmemethylene) hydroxylamme chlonde. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- O-Benzyl-N-[5-9':1'' ,N' -dimethylcarbamoyl)hy?roxy-1-
bamoyl)hydroxy-1-ethyl-2-pyridinemethylene] by- ~ethyl-2-pyndmemethylene] hydroxylamme chlo-
droxylamine chloride. nde. 
O-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- 0-Benzyl-N-[5-(N' ,N' -diethylcarbamoyl)hydroxy-1-
bamoyl)hydroxy-1-benzyl-2-pyridinemethylene] by- 40 n_iethyl-2-pyridinemethylene] hydroxylamine chlo-
droxylamine bromide. nde. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- 0-Benzyl-N-[ 5-(N' ,N' -difluoroethylcarbamoyl)hy-
bamoyl)hydroxy- l ,6-dimethyl-2-pyridinemethylene] ?roxy-1-~ethy 1-2-pyridinemethylene] hydroxylam-
hydroxylamine chloride. me chlonde. 
0-(p-Methoxybenzy 1)-N-[3-(N' ,N' -dimethylcar- 45 0-(Diphenylmethyl)-N-[ 5-(N' -isopropylcarbamoyl)hy-
bamoyl)hydroxy-1-ethyl-6-methyl-2-pyridinemethy- droxy-1-methy 1-2-pyridinemethylene] hydroxylam-
lene] hydroxylamine chloride. ine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- 0-(Diphenylmethyl)-N-[ 5-[N' -(2-fluoroethyl)car-
bamoyl)hydroxy- l-benzyl-6-methyl-2- bamoyl]hydroxy-1-methyl-2-pyridinemethylene] hy-
pyridinemethylene] hydroxylamine bromide. 50 droxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- 0-(p-Methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-( 1-naphthylmeth yl)-2- bamoyl)hydroxy-1-meth yl-2-pyridinemethylene] hy-
pyridinemethylene] hydroxylamine chloride. droxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N',N'-dimethylcar- O-(p-Methoxybenzyl)-N-[5-(N',N'-dimethylcar-
bamoyl)hydroxy-l-(2-methyl-1-naphtylmethyl)-2- 55 bamoyl)hydroxy- l-ethyl-2-pyridinemethylene] hy-
pyridinemethylene] hydroxylamine chloride. droxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- 0-(p-Methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-diphenylmethyl-2- bamoyl)hydroxy-l-benzyl-2-pyridinemethylene] hy-
pyridinemethylene] hydroxylamine chloride. droxylamine bromide. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- 60 0-(p-Methoxybenzyl)-N-[5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(2-hydroxy-4-nitro benzyl)-2- bamoyl)hydroxy-1-( 1-naphtylmethyl)-2-
pyridinemethylene] hydroxylamine chloride. pyridinemethylene] hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- 0-(p-Methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(p-carboxy benzyl)-2- bamoyl)hydroxy-1-(2-methyl-1-naphtylmethyl)-2-
pyridinemethylene] hydroxylamine chloride. 65 pyridinemethylene] hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar- 0-(p-Methoxybenzy 1)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(p-cyanobenzyl)-2- bamoyl)hydroxy-1-diphenylmethyl-2-
pyridinemethylene] hydroxylamine chloride. pyridinemethylene] hydroxylamine chloride. 
5,290,942 
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0-(p-Methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl )hydroxy-1-(2-hydroxy-4-nitro benzyl)-2-
pyridinemethylene] hydroxylamine chloride. 
0-(p-Methoxybenzyl)-N-[ 5-(N' ,N' -dimethy lcar-
bamoyl)hydroxy-1-(p-carboxy benzyl)-2-
pyridinemethylene] hydroxylamine chloride. 
O-(p-Methoxybenzyl)-N-[5-(N',N'-dimethylcar-
bamoyl)hydroxy-l-(p-cyanobenzyl)-2-
pyridinemethylene] hydroxylamine chloride. 
O-Benzyl-N-(l-benzyl-3-hydroxy-2-pyridinemethy-
lene) hydroxylamine bromide. 
O-Benzyl-N-(l-benzyl-5-hydroxy-2-pyridinemethy-
lene) hydroxylamine bromide. 
2-[[ (Aminocarbon yl)hydrazono ]methyl]-3-h ydroxy-1-
methyl pyridinium chloride (3a). 
2-[[ (Aminocarbonyl)hydrazono ]methy l]-5-hydroxy-1-
methyl pyridinium chloride. 
2-[[(Aminothiocarbonyl)hydrazono ]methy 1]-3-
hydroxy-1-methyl pyridinium chloride. 
2-[[(Aminothiocarbonyl)hydrazono]methyl]-5-
hydroxy-l-methyl pyridinium chloride. 
2-Hydrazonomethyl-3-hydroxy-l-methyl pyridinium 
chloride. 
2-[[(N,N-Dimethylaminothiocarbonyl)hydrazono]me-
thyl]3-hydroxy-l-methyl pyridinium chloride. 
2-[[(N-Ethylaminothiocarbonyl)hydrazono]methyl]-3-
hydroxy-1-methyl pyridinium chloride. 
5 3-Hydroxy-1-methyl-2-[[ (N-naphtylaminocarbonyl)hy-
drazono ]methyl] pyridinium chloride. 
2-[[[N-( 1-Chloro-2-naphtyl)amino 
drazono]methyl]-3-hydroxy-1-methyl 
chloride. 
carbonyl]hy-
pyridinium 
10 5-Hydroxy-1-methyl-2-[[(N-phenylaminothiocar-
bonyl)hydrazono]methyl] pyridinium chloride. 
2-[[(N,N-Diphenylaminocarbonyl)hydrazono]methyl]-
5-hydroxy-1-methyl pyridinium chloride. 
2-[[(N ,N-Dimethylaminothiocarbonyl)hydrazono ]me-
15 thyl]-5-hydroxy-1-methyl pyridinium chloride. 
2-[[(N-Ethylaminothiocarbonyl)hydrazono]methyl]-5-
hydroxy-1-methyl pyridinium chloride. 
5-Hydroxy-1-methyl-2-[[(N-naphtylaminocarbonyl)hy-
drazono ]methyl] pyridinium chloride. 
20 2-[[[N-(l-Chloro-2-naphtyl)amino 
drazono ]methyl]-5-hydroxy-1-methyl 
carbonyl]hy-
pyridinium 
2-Hydrazonomethyl-3-hydroxy-1,6-dimethyl pyridin- 25 ium chloride. 
chloride. 
1-Methyl-2-[[(N-phenylaminocarbonyl)hydrazono]-
methyl] pyridinium chloride (3d). 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N-dime-
thylcarbamoyl)hydroxy-1-methyl pyridinium chlo-
ride (4a). 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N-dime-
2-Hydrazonomethyl-5-hydroxy-l-methyl pyridinium 
chloride. 
1-Methyl-2-(3-hydroxy-1-methyl-2-pyridinemethylene) 
hydrazine chloride. 
1-Methyl-1-phenyl-2-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine chloride. 
l, l-Diphenyl-2-(3-hydroxy-1-methyl-2-pyridinemethy-
lene) hydrazine chloride. 
l-(2,4-Dinitrophenyl)-2-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine chloride. 
1-Naphtyl-2-(3-hydroxy- l-methy 1-2-pyridinemethy-
lene) hydrazine chloride. 
1-Methy 1-2-( 5-hydroxy-1-methyl-2-pyridinemethylene) 
hydrazine chloride. 
1-Methyl-l-phenyl-2-(5-hydroxy-l-methyl-2-
pyridinemethylene) hydrazine chloride. 
1, 1-Diphenyl-2-(5-hydroxy-1-methyl-2-pyridinemethy-
lene) hydrazine chloride. 
l-(2,4-Dinitrophenyl)-2-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine chloride. 
l-Naphtyl-2-(5-hydroxy-1-methy 1-2-pyridinemethy-
lene) hydrazine chloride. 
l-Methyl-2-(1,6-dimethyl-3-hydroxy-2-pyridinemethy-
lene) hydrazine chloride. 
l-Methyl-l-phenyl-2-(1,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydrazine chloride. 
1,1-Diphenyl-2-(1,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydrazine chloride. 
3-Hydroxy- l-methyl-2-[[ (N-phenylaminocarbonyl)hy-
drazono ]methyl] pyridinium chloride (3b). 
1,6-Dimethyl-3-hydroxy-2-[[(N-phenylaminocarbonyl)-
hydrazono]methyl] pyridinium chloride. 
5-Hydroxy- l-methyl-2-[[ (N-phenylaminocarbonyl)hy-
drazono ]methyl] pyridinium chloride. 
3-Hydroxy-l-methyl-2-[[(N-phenylaminothiocar-
bonyl)hydrazono ]methyl] pyridinium chloride. 
2-[[(N,N-Diphenylaminocarbonyl)hydrazono]methyl]-
3-hydroxy-1-methyl pyridinium chloride. 
1,6-Dimethyl-3-hydroxy-2-[[(N-phenylaminothiocar-
bonyl)hydrazono]methyl] pyridinium chloride. 
1,6-Dimeth yl-2-[[ (N ,N -diphenylaminocarbonyl)hy-
drazono ]methyl]-3-hydroxy pyridinium chloride. 
thylcarbonyl)hydroxy-l,6-dimethyl pyridinium chlo-
30 ride. 
2-[[(Aminocarbonyl)hydrazono]methyl]-5-(N,N-dime-
thylcarbamoyl)hydroxy-1-methyl pyridinium chlo-
ride. 
3-(N ,N-Dimethylcarbamoyl)hydroxy-1-methyl-2-[[ (N-
35 phenylaminocarbonyl)hydrazono]methyl] pyridin-
ium chloride ( 4b ). 
5-(N ,N-Dimethylcarbamoyl)hydroxy-1-methyl-2-[[ (N-
phenylaminocarbonyl) hydrazono ]methyl]-
pyridinium chloride. 
40 2-(3-Hydroxy-1-methyl-2-pyridinemethylene)-1-[2-(1-
pyridinium)acetyl]hydrazine dichloride (Sa). 
2-(1,6-Dimethyl-3-hydroxy-2-pyridinemethylene)-1-[2-
(1-pyridinium)acetyl]hydrazine dichloride. 
2-(5-Hydroxy-1-methyl-2-pyridinemethylene)-1-[2-(1-
45 pyridinium)acetyl]hydrazine dichloride. 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene )-1-[2-
(trimethylammonium)acetyl]hydrazine dichloride. 
1-[2-( 4-Chloro-1-pyridinium)acetyl]-2-(3-h ydroxy-1-
methyl-2-pyridinemethylene )hydrazine dichloride. 
50 2-(1,6-Dimethyl-3-hydroxy-2-pyridinemethylene)-1-[2-
(trimethylammonium)acetyl]hydrazine chloride. 
2-(1,6-Dimethyl-3-hydroxy-2-pyridinemethylene )-1-[2-
( 4-chloro-1-pyridinium)acetyl]hydrazine dichloride. 
1-[2-(3-Carboxy-l-isoquinolinium)acetyl]-2-(3-hydroxy-
55 1-methyl-2-pyridinemethylene)hydrazine dichloride. 
1-[2-(2-Carboxy-4-methoxy-1-quinolinium)acetyl]-2-(3-
hydroxy-1-methyl-2-pyridinemethy Jene )hydrazine 
dichloride. 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene)- l-[2-(3-
60 hydroxy-1-pyridinium)acetyl]hydrazine dichloride. 
2-(3-Hydroxy-1-methyl-2-pyridinemethylene)- l-[2-( 1-
methyl-1-piperidinium)acetyl]hydrazine dichloride. 
2-(5-Hydroxy-1-methyl-2-pyridinemethylene)- l-[2-
(trimethylammonium)acetyl]hydrazine dichloride. 
65 1-[2-(4-Chloro-1-pyridinium)acetyl]-2-(5-hydroxy-1-
methyl-2-pyridinemethylene)hydrazine dichloride. 
1-[2-(3-Carboxy-1-isoquinolinium)acetyl]-2-(5-hydroxy-
1-methyl-2-pyridinemethylene)hydrazine dichloride. 
5,290,942 
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1-[2-(2-Carboxy-4-methoxy-l-quinolinium)acetyl]-2-( S-
hydroxy-1-methy 1-2-pyridinemethylene )hydrazine 
dichloride. 
14 
zyl group to the aldoxime of 3-hydroxy-2-PAM (lb) 
improves binding and lb has an ICso of SOO µM with 
electric eel AChE. The methylaldoxime Jc did not 
inhibit either enzyme at concentrations up to 1 mM. 2-(S-Hydroxy- l-methyl-2-pyridinemethylene)- l-[2-(3-
hydroxy- l-pyridinium)acetyl]hydrazine dichloride. 
2-(S-Hydroxy-l-methyl-2-pyridinemethylene)-1-[2-( 1-
methyl-1-piperidinium)acetyl]hydrazine dichloride. 
2-( l-Methyl-2-pyridinemethylene )-1-[2-( 1-pyridinium-
)acetyl]hydrazine dichloride (5b). 
5 Without the 3-hydroxy substituent, tighter binding oc-
curs and K1values of 40 µMand JOO µM were observed 
with eel and human enzymes respectively for the benzyl 
aldoxime la. 
The bis-pyridinium acyl hydrazones Sa-b were the 
O-Benzyl-N-(l,6-dimethyl-3-hydroxy-2-pyridineme-
thylene)hydroxylamine chloride. 
10 tightest binding reversible inhibitors with Sa having K1 
values of IO and 20 µM with electric eel and human 
erythrocyte AChE, respectively. However, 3-hydroxy 
substitution did not have the same effect on acyl hydra-
It has been found that the novel pyridinium com-
pounds of this invention are good acetylcholinesterase 
inhibitors in vitro as shown in Tables I and II. The 
pyridinium compounds also have good activity in vivo 15 
as prophylactics and antidotes against nerve agent poi-
soning as shown in Tables Ill-VI. 
Competitive Inhibition of Acetylcholinesterase 
The reversible inhibition studies on electric eel and 20 
human erythrocyte AChE were performed at 2S± l 0 C. 
in pH 7.6, O.IM phosphate buffer containing 4% ethanol 
using S-acetyl thiocholine as a substrate (Ellman, G. L., 
Courtney, D., Andres, V., and Featherstone, R. M., 
Biochem. Pharmaco/. 1961, 7, 88). For analysis of AChE 25 
inhibitory potency, electric eel AChE was dissolved in 
buffer. Human erythrocyte AChE was dissolved in a 
O.OlM borate buffer (pH 10.2) containing 0.01 % prote-
ase free bovine serum albumin. 5,5'-Dithiobis(2-
nitrobenzoic acid) (DTNB) and S-acetylthiocholine 30 
were prepared in phosphate buffer. All inhibitor solu-
tions were also dissolved in phosphate buffer; some 
required the addition of 9S% ethanol. Increasing absor-
bance during substrate hydrolysis was monitored on a 
Varian DMS-90 spectrometer. Duplicate studies were 35 
performed on separate days using fresh solutions. No 
time dependent inhibition was observed over a period 
of at least one hour. Using three different substrate 
concentrations and four inhibitor concentrations, a 
Dixon plot (I/activity vs. inhibitor cone.) was made 40 
and the K1values determined. The K1value is the disso-
ciation constant of the enzyme-inhibitor complex. In-
hibitors with lower K1 values are more potent. In the 
case of poor inhibitors an ICso was determined by plot-
ting AChE activity vs inhibitor concentration. Only 45 
values between 10% and 90% inhibition were used. The 
exact procedure is as follows. 
First, 20 µL of S-acetylthiocholine (0.07SM) and 100 
µL of DTNB (O. IOM) were mixed together with phos-
phate buffer. Inhibitor was then added and the solution 50 
mixed well. Next, SO µL of electric eel AChE (l.S 
units/mL) was added and the solution mixed again. 
With human enzyme, 20 µL of a 2 units/mL stock solu-
tion was added. Increasing absorbance was monitored 
at 412 nm. Controls were used for each run in the case 55 
of inhibitors that absorb highly at 412 nm. Hydrolysis 
rates of all inhibitors were negligible. Total volume and 
organic solvent, if any, was kept constant. 
Aldoximes (la,b,d,e) showed pure competitive inhibi-
tion of AChE whereas the semicarbazones (3a,b, 4b) 60 
and acyl hydrazones (Sa, Sb) showed mixed-type inhibi-
tion of AChE (linear, noncompetitive). Results are sum-
marized in Table I. 
The 3-hydroxy substituted aldoximes did not inhibit 
either enzyme well, but did show some selectivity for 65 
the electric eel enzyme. The 3-hydroxy derivative of 
2-PAM was also tested and did not inhibit either en-
zyme at concentrations up to I mM. Addition of a ben-
zones as with the aldoximes. In this case a 3-hydroxy 
group improved the binding to AChE. The complex 
kinetics of Sb indicate at least two different binding 
modes for this inhibitor. At concentrations up to 75 µM, 
Sb acts as a noncompetitive inhibitor. However, at 
higher concentrations, Sb is an uncompetitive inhibitor. 
Only noncompetitive kinetics were observed for Sa. 
All of the semicarbazones (3a,b, 4b) also exhibited 
noncompetitive kinetics. In addition, multiple binding 
was observed and compound 3b had two distinct K1 
values of 30 µM and 340 µM with electric eel AChE. 
Addition of a phenyl group to give the semicarbazone 
3b resulted in a decrease of the I Cso to 240 µM with the 
human enzyme. From the kinetic results, it appears that 
binding in a hydrophobic pocket near the active site is 
the most important interaction for the semicarbazones. 
Compound 4b is the most indicative of this trend. Un-
like all other carbamates, it is not a time dependent 
inhibitor indicating that its position near the active site 
serine is not equivalent to that occupied by the aldox-
imes 2a-c in the E.I complex. Also, the 3-hydroxyl 
group does not negatively influence binding as with the 
3-hydroxy aldoximes which further indicates that bind-
ing of the semicarbazones is different from the aldox-
imes. 
Irreversible Inhibition of Acetylcholinesterase 
The irreversible inhibition studies of electric eel and 
human erythrocyte AChE were performed at 25 ±I ° C. 
in O.lM phosphate buffer. Inhibitor and enzyme were 
incubated in a buffer solution of 1.0 mL total volume 
and 100 µL aliquots were taken at 1 min intervals. The 
aliquots were added to freshly prepared assay solutions 
containing 20 µL of S-acetylthiocholine, 100 µL of 
DTNB, and 2280 µL of buffer. Increasing absorbance 
was monitored at 412 nm. Pseudo first order inhibition 
constants were determined by measuring the enzymatic 
activity of acetylcholinesterase after incubating the 
enzyme with inhibitor for various time periods. Second 
order inhibition rate constants kobsl[I] are reported in 
Table II. Inhibitors with higher kobsl[I] values are more 
potent. Half-lives for inactivation ranged from 10.8 min 
for 4a to about 9 sec for 2c. The kobsl[I] for 2c was 
estimated at > 110,000M- ls-1 because its rapid inacti-
vation of AChE made it difficult to accurately deter-
mine its inhibitory potency. Compounds 2a-c are novel 
analogs of 2-PAM that also incorporate a dimethylcar-
bamyl substituent that reacts covalently with AChE. 
Compounds 2a and 2c have greater anti AChE activity 
in vitro with human AChE than either pyridostigmine 
or physostigmine. A notable selectivity for the human 
enzyme was observed for all of the carbamates. The 
semicarbazone 4a inactivated AChE very slowly. In 
contrast, the phenyl substituted semicarbazone carba-
mate 4b was not a time dependent inhibitor of AChE 
15 
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rable or better protection against GD than the positive 
control, pyridostigmine. 
Carbamate derivatives 2a-2c and carbamate semicar-
bazone 4b showed excellent activity in the oral pretreat-
over a period of l.S hours, unlike all other carbamates 
tested. Both compounds have similar K1 values with 
electric eel AChE; 4a has a K1of 100 µMand 4b has a 
K1 of 8S µM. A K1 for the human enzyme could not be 
determined for 4a because of its rapid inactivation of 
AChE at inhibitor concentrations exceeding 10 times 
the enzyme concentration. 
Animal Studies-Pretreatment Activity 
5 ment studies. They afforded 80-100 survival rates at 120 
min prior to nerve agent challenge while pyridostig-
mine alone allowed no survival. In contrast to its good 
activity in the i.m. studies, bis-pyridinium acyl hydra-
All animal studies were carried out at Battelle, Inc., in 10 
Columbus, Ohio. The results of in vivo mouse evalua-
tions against GD for the compounds tested as intramus-
cular (i.m.) or oral pretreatment agents are given in 
Tables III and IV respectively and were obtained as 
follows. Male ICR mice from Charles River (20 to 30 g 15 
average weight) were treated with three different doses 
of the pyridinium test compound i.m. lS or 60 min, or 
by gavage 30 or 120 min before challenge with a dose of 
2XLDso of GD (LDso=98 µg/kg without atropine, 
zone Sa waS not good as an oral pretreatment agent. 
This may be due to fast clearance from the animal re-
quiring higher doses that approach the toxic dose. 
Oximes la-lfand semicarbazones 3b, 3c and 3d were 
inactive in the i.m. pretreatment assay. In the case of 
substituted oxime derivatives a 3-hydroxy substituent 
significantly reduces drug toxicity (la> lb). On the 
other hand increasing the steric bulk of the oxyimino 
substituent increases drug toxicity (lb> le). 
Animal Studies-Reactivator Activity 
LDso= 130 µg/kg with 11.2 mg/kg of atropine). The 24 20 The results of in vivo mouse evaluations against GD 
h LDso of the test compounds administered i.m. or and GA for the compounds tested as OP reactivators 
orally were determined using S-7 dose groups with S are given in Tables V and VI and were obtained as 
animals per dose. As a negative reference treatment, follows. Male ICR mice from Charles River (20 to 30 g 
saline was administered instead of the test compound. average weight) were treated with the pyridinium test 
As a positive control for survival, pyridostigmine (0.1 25 compound at three different doses administered i.m. 10 
mg/kg, i.m.; 0.82 mg/kg, orally) was adminstered to a seconds after challenge with 2XLDso of GD or GA 
separate group of animals. All pretreatment groups (aqueous solution containing 0.9% NaCl). The test 
received atropine sulfate (11.2 mg/kg) and 2-PAM (2S compound was always given simultaneously with atro-
mg/kg) i.m. exactly 10 seconds after -GD challenge, pine sulfate (11.2 mg/kg). As a negative reference treat-
using a total dose volume of O.S mL/kg body weight. 30 ment group, atropine sulfate (11.2 mg/kg) and 2-PAM 
All animals were allocated to pretreatment cells in a (2S mg/kg) were given without the pyridinium test 
randomized block design. Groups often mice were used compound (no mice survive). As a positive control for 
in each experiment and survivors in each group were survival, HI-6 (9.6 mg/kg) was administered with atro-
noted after 24 h. The 24-hour survival of animals pre- pine sulfate (11.2 mg/kg) to a separate group of animals. 
treated with each dose of the pyridinium test compound 35 All injections were administered i.m. using a dose vol-
was compared with the 24-hour survival observed in ume of 0.S mL/kg body weight. All animals were allo-
the negative reference pretreatment group. A survival cated to treatment cells in a randomized block design. 
difference of at least four is required to identify im- Groups of ten mice were used in each experiment and 
proved efficacy of the candidate over that observed survivors in each group were noted after 24 h. The 
with the negative reference pretreatment. 40 24-hour survival of animals injected with each dose of 
Compounds 2a-d, 4a-b, Sa-b were excellent pretreat- test compound was compared to the 24-hour survival 
ment agents, affording significant protection against a observed in the negative reference treatment cell. A 
dose of 2 X LDso of GD. In all cases saline solution was survival difference of at least four is required to identify 
used as the baseline standard (all mice die) and pyrido- improved efficacy of the candidate over that observed 
stigmine as the positive control for survival (80-100% 45 with the reference treatment. An alternate procedure 
of the mice survive). used on some compounds was the adjunct efficacy test: 
Carbamate derivatives 2a-2d showed 70 to 90% sur- the pyridinium test compound was always given simul-
vival rates at selected doses. After lS min pretreatment taneously with atropine sulfate (11.2 mg/kg) and 
with compound 2a, 2b, or 2d 90% of mice survive a 2-PAM (2S mg/kg). The rest of the procedure is as 
challenge of2XLDsoofGD at comparable fractions of 50 described above. 
the LDso's for these compounds (1/SS LDso of 2a, 1/72 Carbamate oxime derivatives 2a, 2b, semicarbazone 
LDso of 2b, 1/67 LDso of 2d). On the other hand, com- 3a, carbamate semicarbazone 4b and bis-pyridinium 
pound 2c afforded a 70% survival rate under the same acyl hydrazones Sa and Sb showed significant activity 
conditions but at a 1/16, 700 fraction of its LDso. Carba- as GD reactivators (Table V). The last two also showed 
mate semicarbazones 4a and 4b and the acyl hydrazones 55 significant activity as GA reactivators (Table VI). 
Sa and Sb were also very good i.m. pretreatment agents. 2-PAM was used as the baseline standard while the 
Carbamate semicarbazone 4a was exceptionally good as positive control used HI-6 as the reactivator. Carba-
a pretreatment agent. Acyl hydrazones Sa and Sb were mate oximes 2a and 2b affored SO% and 70% survival 
also excellent pretreatment agents but their effective rates respectively at a dose 1/16 of their LDso's. They 
doses were much closer to their toxic doses than was 60 were also the most toxic of the five derivatives that 
the case with 4a. Except for 4a, all remaining pretreat- showed activity as OP reactivators. The greater inhibi-
ment agents were more effective when given lS min tion of AChE displayed by 2a compared to 2b is 
prior to Soman challenge. The decrease in efficacy at 60 matched by its greater toxicity. A 62 fold increase in 
min may be due to transformation of the drugs to inac- kobsl[I] accompanied by a 44 fold increase in toxicity 
tive metabolites and/or clearance from the animal. It 65 indicates that in the case of irreversible inhibitors a 
was most noticeable for acyl hydrazones Sa and Sb, compromise must be reached between the degree of 
which are doubly charged and can be excreted more inhibition that affords protection from the OP agent and 
rapidly. All seven pretreatment agents offered compa- that which prevents the enzyme from performing its 
17 
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physiological role. It is noteworthy that 2a and 2b must formulation and on the object of the therapy or prophy-
be acting as prodrugs of the actual OP reactivator since !axis: The amount of the individual doses as well as the 
they do not possess a nucleophile themselves that can administration is best determined by individually asses-
displace the OP from the active site of AChE. In the sing the particular case. 
semicarbazone series, a 3-hydroxy substituent increases 5 The pharmaceutical compositions containing the ac-
in vivo activity (3a > 3c ). Semicarbazone 3a afforded tive ingredient may be in a form suitable for oral use, for 
70% survival rate at 1/25 of its LDso when given 10 example as tablets, troches, lozenges, aqueous or oily 
seconds after a challenge of 2 X LDso of Soman. Semi- suspensions, dispersible powders or granules, emulsions, 
carbazone 3a was also an excellent reactivator when hard or soft capsules or syrups or elixirs. Dosage levels 
tested in the adjunct assay: it afforded 90% survival rate 10 of the order to 0.2 mg to 140 mg per kilogram of body 
when administered along with 2-P AM (25 mg/kg) 10 weight per day are useful in the treatment of above-
seconds after Soman challenge. This combination of indicated conditions (10 mg to 7 gms per patient per 
drugs was more effective than Hl-6 in counteracting day). The amount of active ingredient that may be com-
Soman intoxication. Carbamate semicarbazone 4b af- bined with carrier materials to produce a single dosage 
forded 50% survival rate at 1/16 of its LDsowhen given 15 form will vary depending upon the host treated and the 
10 sec after a challenge of 2 X LDso of Soman. Bis- particular mode of administration. 
pyridinium acyl hydrazone 5a was an excellent GD For injection, the therapeutic amount of pyridinium 
reactivator. It afforded 90% survival rate at a dose of 73 d f th t · t" ill 11 b · Ilk ( . compoun s o e presen mven ton w norma y e m 
mmo g approx. 1/8 LDso) when given 10 seconds the dosage range from 0.2 mg to 140 mg/kg of body 
after Soman challenge. 20 · h Ad · · · · d b · · 
Two h d 2 PAM d · t" (lf 1 ) we1g t. mm1strat1on 1s ma e y mtravenous, mtra-y roxy - enva 1ves , g were pre- 1 b · · · · pared and tested for comparison with 2-PAM and with muscu ~r or su cu~.eous tnJect1on. Accordm.gl.y, p~ar-
the Other Subst.t ted · d · t" rt d . th" maceut1cal compos1t1ons for parenteral admm1strat1on 1 u ox1me enva 1ves repo e m 1s ill . . · " 
study. The parent 2-PAM is not an effective reactivator w conta1? ~n. a smgle dosage iorm about I? mg ~o 7 
against Soman due to rapid "aging" of the inhibited 25 gms o~ l:'ynd1mum c~mP?und ~f the present mvent10~. 
AChE. Adding a hydroxy substituent to the 3 or 5 In add1t1on ~~ the a~t1ve mgred1ent, ~hese pharmaceuti-
position of 2-PAM resulted in no improvement in reac- cal compos1t10ns w1~l usually conta1~ a buffer, e.g. a 
tivating ability concurrent with a small increase in tox- phosphate buffer wh1.ch keeps ~he pH m ~he range fr?m 
icity. In addition, these derivatives were not signifi- 3.5 to .7 a?d also ~odm~ chlonde, manmtol or sorb1tol 
cantly better than 2-PAM in the pretreatment assay. 30 for adJUStmg. t.he 1sotomc. pressur~. . 
The carbamate of 5-hydroxy-2-PAM chloride, com- A compos1t10n for top1c~l applt~at10? can be fo~u-
pound 2d, incorporates the structural features of pyri- lated. as an aqueo~s solution, 10~1?n, .Jelly or an 01ly 
dostigmine and 2-PAM. It afforded 90% survival rate at solution or suspent10n. A compos1t10n m the form of an 
a dose 1/67 of its LDso when given 15 or 60 minutes ~queous solution is obtained by d.issolvi!1g t~e pyridin-
prior to Soman challenge. 35 tum compounds of the present mvent1on m aqueous 
· buffer solution of pH 4 to 8.5 and if desired, adding a 
Summary-Animal Studies polymeric binder. An oily formulation for topical appli-
The in vivo activity described herein for some of the cation is obtained by suspending the pyridinium com-
novel pyridinium compounds of this invention can be pounds of the present invention in an oil, optionally 
summarized as follows: eight compounds (2a-2d, 4a, 4b, 40 with the addition of a swelling agent such as aluminium 
5a, 5b) were effective i.m. prophylactics against GD; stearate and/or a surfactant. 
four compounds (2a-2c, 4b) were effective oral prophy-
lactics against GD; six compounds (2a, 2b, 3a, 4b, 5a, 
5b) were good in vivo reactivators against GD; two 
compounds (5a, 5b) were good in vivo reactivators 45 
against GA; five compounds (2a, 2b, 4b, 5a, 5b) were 
both excellent prophylactics and good reactivators 
against GD. Compounds 4a and 3a form a set in which 
an excellent prophylactic (4a) is transformed by AChE 
into a good OP reactivator (3a). Structural require- 50 
ments for prophylactic activity are a carbamate moiety 
and/or a second quaternary center. Since carbamates 
may act as prodrugs for the actual reactivators (i.e. 3a 
and 4a), the latter structural requirements also apply for 
AChE reactivators in addition to semicarbazones hav- 55 
ing a free OH group in the pyridine ring. 
Drug Delivery 
For the prophylaxis of OP poisoning and for the 
treatment of OP overdose, Myasthenia Gravis, senile 60 
dementia such as is seen in Alzheimer's and adult 
Down's syndrome patients, high blood pressure, glau-
coma, and abdominal distension the pyridinium com-
pounds of the present invention may be administered 
orally, topically or parenterally. The term parenteral as 65 
used includes subcutaneous injection, intravenous, in-
tramuscular, intrasternal injection or infusion tech-
niques. The dosage depends primarily on the specific 
Synthetic Methods 
All common chemicals and solvents were reagent 
grade or better. The purity of each compound was 
checked by IH NMR, mass spectroscopy, thin-layer 
chromatography (TLC), and elemental analysis. Results 
are consistent with the proposed structures. Melting 
points were obtained on a Biichi capillary melting point 
apparatus and are uncorrected. IH NMR spectra were 
recorded with a Varian Gemini 300 MHz NMR spec-
trometer; chemical shifts are reported in parts per mil-
lion (8) from an internal tetramethylsilane standard. 
Mass spectra were recorded on a Varian Mat 112s spec-
trometer. Elemental analyses were performed by Atlan-
tic Microlab in Atlanta, Ga. 3-Hydroxy-2-pyridine car-
boxaldehyde (Stempel, A. and Buzzi, E. C., J. Am. 
Chem. Soc. 1949, 71, 2969; Ginsburg, S. and Wilson, I. 
B., J. Am. Chem. Soc. 1957, 79, 481, incorporated herein 
by reference) was prepared from 3-hydroxy-2-hydrox-
ymethyl pyridine by oxidation using manganese dioxide 
(Demerseman, P., Kiffer, D., Debussche, L., Lion, C., 
Royer, R., and S.-Roumanou, H., Eur. J. Med. Chem. 
1988, 23, 63, incorporated herein by reference). Girard's 
reagent "P" [1-(carboxymethyl)pyridinium chloride], 
4-phenylsemicarbazide, and 3-hydroxy-6-methyl-2-
pyridinemethanol were purchased from Aldrich Chem-
ical Company. 
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The oxime, hydrazone, semicarbazone and acyl hy-
drazone derivatives described herein were prepared 
using standard methodology. Many different 0-sub-
stituted hydroxylamines can be prepared by known 
procedures (Grochowski, E. and Jurczak, J., Synthesis 5 
1976, 682; Schumann, E. L., Heinzelman, R. V., Greig, 
M. E., and Veldkamp, W., J. Med. Chem. 1964, 7, 329, 
incorporated herein by reference) to afford the various 
substituted oximes described herein. Several substituted 
hydrazines are commercially available (i.e. methylhy- 10 
drazine, 1, 1-d!methylhydrazine, 1, 1-diphenylhydrazine, 
from Aldrich Chemical Co.) and other can be synthe-
sized by standard methodology (i.e. Hoffman degrada-
tion of ureas, reduction ofN-nitroso compounds, reduc-
tion of diazonium salts) to afford the hydrazone deriva- 15 
tives described herein. Several substituted semicarba-
zides are commercially available (i.e. 4-phenyl-3-thi-
osemicarbazide, 4,4-diphenylsemicarbazide, 4,4-dimeth-
yl-3-thiosemicarbazide, 4-ethyl-3-thiosemicarbazide) 
and others can be synthesized by standard methodology 20 
(reduction of N-nitro ureas). Commercially available 
Girard's reagent "T" [(carboxymethyl) trimethylammo-
nium chloride hydrazide] can be used instead of Gir-
ard's reagent "P" to obtain 2-(trimethylammonium)a-
cetyl hydrazine derivatives similar to Sa and Sb. Other 25 
hydrazides for the synthesis of various acyl hydrazones 
described herein can be made by known methodology 
mL, 0.08 mo!) was added to this solution and the result-
ing mixture was stirred at room temperature for 10 h. 
Excess water was removed under vacuum and the resi-
due was fractionally distilled under reduced pressure 
(14 mm Hg). The product was obtained as a yellow oil 
in the fraction distilling at 8S 0 -90° C. (11.3 g, 67% ). IH 
NMR (Me2SO·d6) 8: S.2S (s, 2H), 7.24 (t, IH), 7.32-7.44 
(m, SH), 7.66 (t, IH), 7.78 (d, IH), 8.23 (s, IH), 8.S8 (d, 
lH). 
O-Benzyl-N-(l-methyl-2-pyridinemethylene)hydrox-
ylamine iodide 
Methyl iodide (14.3 mL, 0.23 mol) was added to a 
solution of O-Benzyl-N-(2-pyridinemethylene)hydrox-
ylamine (11.3 g, O.OS mol) in 7S mL of acetonitrile. The 
resulting mixture was heated in a pressure vessel at 6S 0 
C. for 24 h. The solvent was removed in vacuo and the 
residue was triturated with acetone to afford the prod-
uct as a light orange solid (17.2 g, 92%), m.p. 12S 0 -7° C. 
(dee.). IH NMR (Me2SO-d6) 8: 4.36 (s, 3H), S.38 (s, 2H), 
7.36-7.49 (m, SH), 8.09 (t, lH), 8.36 (d, IH), 8.SS (t, lH), 
8.84 (s, lH), 9.00 (d, lH). 
O-Benzyl-N-(l-methyl-2-pyridinemethylene)hydrox-
(Vogel, A. I., in A Textbook of Practical Organic Chemis- . . 
try; Longman Group Limited: London, 1972; pp. Silver cblonde (freshly prepared from 14.'6 g AgN03 
ylamine chloride 
976-978, incorporated herein by reference), which in- 30 and excess cone. HCl) was added to a solution of 16.2 g 
volves the reaction between an amine and ethyl chloro- (O.OS mo!) of O-Benzyl-N-(l-methyl-2-pyridineme-
acetate, followed by reaction with hydrazine hydrate. thylene)hydroxylamine iodide in 800 mL HiO. The 
Conversion of the 3 or S-hydroxy moiety into a carba- suspension was vigorously stirred with a mechanical 
mate .was accomplishe~ usi~g N,N-dimethylcarbamyl stirrer for 4 hat room temperature. The yellow precipi-
chlonde. Other N ,N-d1subst1tuted carbamates can be 35 tate was filtered off and the filtrate was concentrated to 
made by reaction between commercially available tri- dryness and coevaporated several times with acetone. 
phosgene and a disubstituted amine, followed by reac-
tion with the 3 or S-hydroxy pyridine derivative. N- Traces of solvent are removed by evaporation at S0° C. 
monosubstituted carbamates can be prepared by reac- in a rotary evaporator at 0.8 mm Hg overnight. The 
tion of the free 3-0H group on the pyridine ring and any 40 yellow solid that remains (11.63 g) is recrystallized from 
of numerous isocyanates that are commercially avail- EtOH/acetone with scratching to obtain 8.1 g (68%) of 
able. In the case of fluorinated derivatives, the synthesis analytically pure product as beige microscopic needles; 
of the appropiate fluoroalkylamine (some are commer- m.p. 14S0 -6° C. (dee.). Anal. Calcd. for C14H1sClN20 x 
cially available) is required, followed by reaction with HiO: C, 61.87; H, S.93; N, 10.31; Cl, 13.0S. Found: C, 
phosgene to generate the desired isocyanate. Quaterni- 45 61.94; H, S.94; N, 10.31; Cl, 13.10. IH NMR (MeiSO-d6) 
zation of the pyridine nitrogen was carried out using " 38 ( 3H) s 3 ( 2H) 7 36 8 ( H) 8 ( 
. . u: 4. s, , . 8 s, , . -7.4 m, S , .09 t, 
methyl 1od1de in a sealed glass pressure vessel and was 
followed by anion exchange using a biphasic mixture of IH), 8·3.S (d, IH), 8.SS (t, IH), 8.86 (s, IH) •. 9:08 (d, IH). 
silver chloride and the methiodide in acetonitrile/wa- O-(Dtphenylmethyl)-N-(l-methyl-2-pyndmemethy-
ter. Other salts of the pyridinium compounds described lene) hydroxylamine chloride 0-(p-cblorobenzyl)-N-(l-
herein can be made in similar fashion, by methathesis so methyl-2-pyridinemethylene) hydroxylamine chloride 
involving the silver salt of the desired counterion and O-(p-methoxybenzyl)-N-(l-methyl-2-pyridinemethy-
the methiodide formed in the initial alkylation of the lene) hydroxylamine chloride 0-(1-naphtylmethyl)-N-
pyridine nitrogen. The usefulness of this procedure has (l-methyl-2-pyridinemethylene) hydroxylamine chlo-
been studied with 2-PAM derivatives (Kondritzer, A. 55 ride 0-(2-methyl-1-naphtylmethyl)-N-(l-methyl-2-
A., Ellin! R. I., and Edber~, L. J., J. Pharm. ScL 1961, pyridinemethylene) hydroxylamine chloride, 0-(2,3,4-
SO, 109, mco~orated herem by r~ference): trimethoxybenzyl)-N-(l-methyl-2-pyridinemethylene) 
The followmg examples are given to illustrate the h d 1 · bl "d d 0 (3 3 d" h l l) · · d · d 1. · · · y roxy amme c on e, an - , - tp eny propy -mventton an are not mten ed to tmtt tt m any manner: N (l · h 1 2 .d. h 1 ) h d I · 
EXAMPLE 1 
Preparation of 
O-Benzyl-N-(l-methyl-2-pyridinemethylene) 
Hydroxylamine Chloride (la) 
O-Benzyl-N-(2-pyridinemethylene) hydroxylamine. 
0-Benzylhydroxylamine hydrochloride (12.77 g, 0.08 
mo!) was added to a solution of NaOH (3.2 g, 0.08 mo!) 
in 80 mL 1:1 EtOH/H20. Pyridine-2-carbaldehyde (7.6 
- -met y - -pyn memet y ene y roxy amme 
60 chloride can be made by the same procedure replacing 
0-benzyl hydroxylamine in the above example respec-
tively with 0-(diphenylmethyl) hydroxlamine, 0-(p-
cblorobenzyl) hydroxylamine, 0-(p-methoxybenzyl) 
65 hydroxylamine, 0-(1-naphtylmethyl) hydroxylamine, 
0-(2-methyl-1-naphtylmethyl) hydroxylamine, 0-
(2,3,4-trimethoxybenzyl) hydroxylamine, and 0-(3,3-
diphenylpropyl) hydroxylamine. 
21 
EXAMPLE2 
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Preparation of 
0-Benzyl-N-(3-hydroxy- l-methyl-2-pyridinemethy-
lene) hydroxylamine chloride (lb) 
O-Benzyl-N-(3-hydroxy-2-pyridinemethylene) 
hydroxylamine 
A solution of 0-benzyl hydroxylamine was prepared 
5 
22 
made by the same procedure substituting 3-hydroxy-2-
pyridine carbaldehyde for 2-formyl-5-hydroxy pyri-
dine. 
EXAMPLE3 
Preparation of 
O-Methyl-N-(3-hydro:xy-1-methyl-2-pyridinemethy-
lene) hydroxylamine chloride (le) 
by dissolving 2 g of sodium hydroxide (0.05 mol) and 8 10 O-Methyl-N-(3-hydroxy-2-pyridinemethylene) g of 0-benzyl hydroxylamine hydrochloride (0.05 mo!) hydroxylamine 
in 50 mL of 50% ethanol-water. To this solution was NaOH (1.62 g, 0.04 mo!) was added to a solution of 
added 6.15 g of 2-formyl-3-hydroxypyridine (0.05 mol). methoxyamine hydrochloride (3.4 g, 0.04 mo!) in 30 ml The mixture was stirred for 3 h at room temperature. 
The precipitate was then filtered and air dried to yield of HiO. 3-Hydroxy-2-pyridine carboxaldehyde (5.0 g, 
10.3 g (90.3%) of pure product; m.p. 64._65• c. 'H 15 0.04 mo!) was added to the clear solution, followed by 
NMR (CDC!) "' 9 ( H 15 mL of EtOH. The reaction mixture was stirred at 3 u: .72 s, 1 , OH); 8.37 (s, lH, 
CH=N); 8.13 (d of d, J =2H, J =4 Hz, lH); 7.33 (m, roo~ .temperature for 15 hand concentrated in vacuo to 
7H); 5.17 (s, 2H, CH2). Anal. Calcd. for c 13H 12N2o2: a 1DJrumum volume (approx. 5 mL). Water (15 mL) was 
C, 68.41; H, 5.30; N, 12.27. Found: c, 68.34; H, 5.32; N, added to this residue and the resulting solution was 
12.21. 20 extracted with EtOAc (4X20 mL). The organic extract 
O-Benzyl-N-(3-hydroxy- l-methyl-2-pyridinemethy-
lene) hydroxylamine chloride 
O-Benzyl-N-(3-hydroxy-2-pyridinemethylene) hy-
droxylamine (2.65 g, 11.6 mmol) was placed in a pres- 25 
sure tube together with 7 g of methyl iodide and 40 mL 
of a 2:3 mixture of EtOH/water. The reaction mixture 
was heated at 65° C. for 20 h and the solvent was then 
removed in vacuo. The residue was triturated with 
acetone to afford 2.50 g (58%) of product as greenish 30 
crystals; m.p. 247° C. (dee.). The methiodide salt (4.90 
g, 13.2 mmol) was dissolved in 22 mL of a l: l mixture 
was dried (MgS04), filtered and concentrated in high 
vacuum to a yellow oil that crystallizes upons cooling in 
a bath of isopropanol-dry ice to yield 4.83 g (79%) of 
product as a white solid; m.p. 186'-7° C. (dee). 'H 
NMR (CDCl3) 8: 9.82 (s, lH), 8.35 (s, lH); 8.21 (d of d, 
lH, J = 1.5 Hz, J =4.5 Hz); 7.30 (d of d, lH, J = 1.5 Hz, 
J=8.5 Hz); 7.19 (d ofd, lH, J=4.5 Hz, J=8.5 Hz). 
O-Methyl-N-(3-hydroxy-l-methyl-2-pyridinemethy-
lene) hydroxylamine iodide 
Methyl iodide (8.9 mL, 0.14 mol) was added to a 
solution of 0-methyl-N-(3-hydroxy-2-pyridinemethy-
lene) hydroxylamine (4.83 g, 32 mmol) in 20 mL of 
acetonitrile. The reaction mixture was heated in a pres-
sure glass bottle at 70° C. for 20 h and then concentrated 
to dryness in vacuo. The resulting yellow solid was 
triturated with acetone and filtered to yield 7.72 g 
(82%) of product which was used in the next step with-
out further purification. 
of acetonitrile and water and freshly made AgCI was 
then added (from 4.0 g AgN03 and excess cone. HCl, 
washed well with water). Additional water (15 mL) 35 
was added to this suspension and the resulting mixture 
was stirred at room temperature for 40 min. The silver 
iodide was removed by filtration and the filtrate was 
concentrated to dryness in vacuo to yield a residue that 
was triturated with acetone. The solid that resulted was 40 
washed well with acetone and dried to yield 3.61 g O-Methyl-N-(3-hydroxy-1-methyl-2-pyridinemethy-
(98%) of product as white crystals; m.p. 146° C. IH Jene) hydroxylamine chloride 
NMR (DMSO-d6) 8: 8.58 (d, lH, J = 5.0 Hz), 8.55 (s, The methiodide obtained in the previous step (7. 72 g, 
lH), 8.20 (d, lH, J =7.3 Hz), 7.90 (d of d, lH), 7.42 (m, 26 mmol) was dissolved in 230 mL of HiO. Freshly 
SH), 5.34 (s, 2H), 4.27 (s, 3H). Anal. Calcd. for 45 made AgCl (7.6 g, 53 mmol) was added to this solution 
C14ff1sN202Cl x HiO: C, 56.65; H, 5.78; N, 9.43; Cl, and the resulting suspension was stirred at room tem-
11.94. Found: C, 56.65; H, 5. 79; N, 9.40; Cl, 11.88. fi l 5 h Th · · fil d d O-(l-Naphtylmethyl)-N-(3-hydroxy-l-methyl-2- perature or . . e reaction mIXture was i tere an 
pyridinemethylene) hydroxylamine chloride, 0-(2- the. filtra~e was concentrated t~ dryness ~ vacuo. Th~ 
methyl-1-naphtylmethyl)-N-(3-hydroxy-l-methyJ-2. 50 white sohd that resulted was.tnturated with warm (40 
pyridinemethylene) hydroxylamine chloride, 0-(2,3,4- C.) acetone ~ndftltered to 1y1eld 4.35 g (83%) of prod-trimethoxybenzyl)-N-(3-hydroxy-l-methyl-2- uct; m.p. 186 -7 C. (dee.). H NMR (DMSO-d6) 8: 8.62 
pyridinemethylene) hydroxylamine chloride, and O- (d, lH, 1=6.0 Hz); 8.48 (s, lH); 8.31 (d, lH, J=8.5 Hz); 
(3,3-diphenylpropyl)-N-(3-hydroxy-l-methyl-2- 7.93 (d of d, lH, J =6.0 Hz, J =8.5 Hz). Anal. Calcd. for 
pyridinemethylene) hydroxylamine chloride can be 55 CsH11N2Cl02: C, 47.41; H, 5.47; N, 13.83; Cl, 17.50. 
made by the same procedure replacing 0-benzyl hy- Found: C, 47.47; H, 5.49; N, 13.76; Cl, 17.43. 
droxylamine in the above example respectively with O-Methyl-N-(5-hydroxy-1-methyl-2-pyridinemethy-
0-(1-naphtylmethyl) hydroxylamine, 0-(2-methyl-1- lene) hydroxylamine chloride can be made by the same 
naphtylmethyl) hydroxylamine, 0-(2,3,4-trimethoxy- procedure replacing 3-hydroxy-2-pyridine aldehyde in 
benzyl) hydroxylamine, and 0-(3,3-diphenylpropyl) 60 the above example with 2-formyl-5-hydroxy pyridine. 
hydroxylamine. 0-( l-Naphtylmethyl)-N-(5-hydroxy- l- 0-[2-( 1-Methyl-1-piperidiniumethyl]-N-(3-hydroxy-1-
methyl-2-pyridinemethylene) hydroxylamine chloride, methyl-2-pyridinemethylene) hydroxylamine dichlo-
0-(2-methyl-1-naphtylmethyl)-N-(5-hydroxy-1-methyl- ride and 0-[2-(trimethyl ammonium)ethyl]-N-(3-
2-pyridinemethylene) hydroxylamine chloride, 0- hydroxy-1-methyl-2-pyridinemethylene) hydroxylam-
(2,3,4-trimethoxybenzyl)-N-(5-hydroxy-l-methyl-2- 65 ine dichloride can be made by the same procedure re-
pyridinemethylene) hydroxylamine chloride, and 0- placing methoxyamine in the above example with 0-[2-
(3,3-diphenylpropyl)-N-(5-hydroxy-l-methyl-2- (1-piperidine)ethyl] hydroxylamine and 0-[2-(dime-
pyridinemethylene) hydroxylamine chloride can be thylamino)ethyl] hydroxylamine. 
5,290,942 
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EXAMPLE4 
Preparation 
O-(p-Chlorobenzyl)-N-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylamine chloride (ld) 
0-(p-Chlorobenzyl)hydroxylamine hydrochloride 
5 
H, 3.49; N, 6.92; Cl, 8.76; I, 31.36. Found: C, 41.62; H, 
3.53; N, 6.92; Cl, 8.71; I, 31.28. 
O-(p-Chlorobenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride 
To a solution of the corresponding pyridinium iodide 
(1.0 g, 2.47 mmol) in CH3CN/H20 (1:1, 15 mL) was 
added freshly made AgCI (from 0.54 g AgN03 and 
cone. HCI). The mixture was allowed to stir at room 
The hydroxylamine hydrochloride was prepared by 
hydrazinolysis of the corresponding benzyloxyphthali-
mide. The phthalimide (15 g, 0.051 mol) was dissolved 10 temperature for 1.5 h. It was then filtered through a bed 
of Celite. The solvent was removed in vacuo. Tritura-
tion of the residue with acetone gave the pure pyridin-
ium chloride (0.72 g) in 93% yield, m.p. 175° C. (dee). 
in DMF (75 mL) and MeOH (260 mL) and warmed to 
60° C. The solution was treated with hydrazine mono-
hydrate (5.7 g, 0.11 mol) and allowed to cool to room 
temperature for 3 h. The mixture was acidified to pH 2 
with 2N HCI and filtered. The filtrate was evaporated 15 
to dryness and treated with 2N NaOH (75 mL). The 
oily product was extracted with ether, and the com-
bined ether extracts were washed with H20, dried over 
anhydrous K2C03, and concentrated in vacuo. The 
resulting oil was treated with ethereal hydrogen chlo- 20 
ride to precipitate the product as a white solid. Recrys-
tallization from EtOH gave the pure hydroxylamine 
hydrochloride as shiny white plates (9.5 g, 96%), m.p. 
235° C. [lit. m.p. 245° C.; Schumann, E. L., Heinzelman, 
R. V., Greig, M. E., and Veldkamp, W., J. Med. Chem. 25 
1964, 7, 329]. IH NMR (CDCl3) d: 7.23 (s, 4H); 5.00 (s, 
2H). 
0-(p-Cyanobenzyl)hydroxylamine hydrochloride, 
0-(2-Hydroxy-4-nitrobenzyl) hydroxylamine hydro-
chloride, and 0-(p-Carboxy benzyl)hydroxylamine hy- 30 
drochloride can be made by the same procedure replac-
ing p-chlorobenzyloxyphtalimide respectively with 
p-cyanobenzyloxyphtalimide, 2-hydroxy-4-nitroben-
zyloxyphtalimide, and p-carboxybenzyl oxyphtalimide. 35 
O-(p-Chlorobenzyl)-N-(3-hydroxy-2-pyridinemethy-
lene) hydroxylamine 
IH NMR (CDCl3/DMSO-d6) 8: 8.67 (m, lH); 8.37 (m, 
lH); 8.00-7.67 (m, lH); 7.37 (s, 4H); 5.3 (s, 2H); 4.33 (s, 
3H). Anal. Calcd. for C14ff14N202C!i: C, 53.68; H, 4.51; 
N, 8.95; Cl, 22.64. Found: C, 53.76; H, 4.56; N, 8.92; Cl, 
22.57. 
O-(p-Cyanobenzyl)-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride, 0-(2-
hydroxy-4-nitrobenzy 1)-N -(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride, and O-(p-
carboxybenzyl)-N-(3-hydroxy-1-methy 1-2-
pyridinemethylene) hydroxylamine chloride can be 
made by the same procedure replacing 0-(p-chloroben-
zyl) hydroxylamine respectively with O-(p-cyanoben-
zyl)-N-(3-hydroxy-2-pyridinemethylene) hydroxylam-
ine, 0-(2-hydroxy-4-nitrobenzyl)-N-(3-hydroxy-2-
pyridinemethylene) hydroxylamine, and O-(p-carbox-
ybenzyl)-N-(3-hydroxy-2-pyridinemethylene) hydroxy-
lamine. O-(p-Chlorobenzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride, O-(p-
cyanobenzyl)-N-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride, 0-(2-
hydroxy-4-nitrobenzyl)-N-( 5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride, and 0-(p-
carboxybenzyl)-N -( 5-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine chloride can be 
made by the same procedure replacing 3-hydroxy-2-
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
EXAMPLE 5 
0-( 4-Chlorobenzyl) hydroxylamine hydrochloride 
(9.75 g, 50 mmol) was neutralized with NaOH (2.0 g, 50 40 
mmol dissolved in 20 mL H20). Ethanol (20 mL) was 
added to solubilize the resulting hydroxylamine. 3-
Hydroxy-2-pyridinealdehyde (6.2 g, 50 mmol) dissolved 
in H20 (150 mL) was added and the mixture heated on Preparation of 
a steam bath for 30 min. The solution was cooled to 45 O-(p-Methoxybenzyl)-N-(3-hydroxy-1-methyl-2-
room temperature. The product crystallized out as long pyrjdinemethylene) hydroxylamine chloride (le) 
pale yellow needles. The mixture was filtered to isolate O-(p-Methoxybenzyl)-N-(3-hydroxy-2-
the pure product (12.5 g, 96%), m.p. 89°-90° C. 1H pyridinemethylene) hydroxylamine. 
NMR (CDCl3) 8: 9.67 (s, lH); 8.33 (s, lH); 7.33-7.13 (m, 0-(p-methoxybenzyl) hydroxylamine (5.55 g, 29 
7H); 5.17 (s, 2H). Anal. Calcd. for C13H11N202Cl: C, 50 mmol; Grochowski et al, 1976 and Schumann et al, 
59.43; H, 4.23; N, 10.67; Cl, 13.49. Found: C, 59.43; H, 1964, vide supra) was added to a solution ofNaOH (1.2 
4.26; N, 10.64; Cl, 13.56. g, 29 mmol) in 15 mL H20. 3-Hydroxy-2-pyridine car-
O-(p-Chlorobenzyl)-N-(3-hydroxy-l-methyl-2- baldehyde (3.6 g, 29 mmol) was then added, followed 
'd' th I ) h d 1 · · d'd by 15 mL of 95% EtOH and 10 mL o( acetone. The pyn meme Y ene Y roxy amme 10 1 e 55 reaction mixture was stirred at room temperature for 4 
A solution of O-(p-chlorobenzyl)-N-(3-hydroxy-2- h and was then poured over 400 mL of crushed ice. A 
pyridinemethylene) hydroxylamine (1.0 g, 3.8 mmol) in beige solid comes out of solution upon scratching the 
EtOH (45 mL) was placed in a glass pressure tube. sides of the beaker. It was filtered, washed with water 
Methyl iodide (1 mL, 16.0 mmol) was then added, and and dried to yield 7.03 g (93%) of product; m.p. 79°-81° 
the tube was sealed tightly. The tube was heated at 69° 60 C. IH NMR (CDCl3) 8: 9.85 (s, lH); 8.38 (s, lH); 8.19 (d 
C. in an oil bath for 20 h. The solution was concentrated of d, lH); 7.36 (d of d, 2H); 7.28 (d of d, lH); 7.18 (d of 
in vacuo. The oily residue was triturated with acetone d, lH); 6.93 (d of d, 2H); 5.15 (s, 2H); 3.82 (s, 3H). 
to give the crude product as a yellow solid (1.46 g, 
95%). Recrystallization from acetone gave the pure 
product as a shiny yellow solid (0.8 g, 52%), m.p. 65 
164°-166° C. IH NMR (CDCl3/DMSO-d6) 8: 8.83-8.67 
(m, 2H); 8.13-7.67 (m, 2H); 7.33 (s, 4H); 5.00 (s, 2H); 
4.43 (s, 3H). Anal. Calcd. for C14ff14N202Cll: C, 41.55; 
O-(p-Methoxybenzyl)-N-(3-hydroxy- l-methyl-2-
pyridinemethylene) hydroxylamine chloride. 
Methyl iodide (7.2 mL, 0.12 mol) was added to a 
solution of O-(p-methoxy)benzyl-N-(3-hydroxy-2-
pyridinemethylene) hydroxylamine (3.72 g, 14 mmol) in 
25 
5,290,942 
26 
of d, lH, J =8.3Hz,J=1.5 Hz); 7.30-7.43 (m, 6H); 5.30 
(s, 2H); 3.06 (s, 3H); 2.97 (s, 3H). 
60 mL of acetonitrile. The resulting mixture was di-
vided into three pressure glass vessels and heated at 70° 
C. for 3 days. The solvent was removed in vacuo and 
the residue was triturated with ether/acetone (3:1); after O-Benzyl~N-[3-(N',N'-dimethylcarbamoyl)hydroxy-1-
drying, the methiodide weighed 4.88 g (85%). It was 5 methyl-2-pyridinemethylene] hydroxylamine iodide 
dissolved in 500 mL HzO and 300 mL of acetonitrile A solution of 2.95 g (9.9 mmol) of O-benzyl-N[3-
and freshly made AgCI (2 eq.) was then added. The (N',N'-dimethylcarbamoyl)hydroxy-2-pyridinemethy-
suspension was stirred at room temperature for 1.5 h Jene] hydroxylamine and 2.8 mL (44 mmol) of methyl 
and then filtered through Celite. The filtrate was con- iodide in 20 mL of acetonitrile was heated at 65° C. in a 
centrated to dryness in vacuo and the residue was tritu- 10 glass pressure bottle for 2 days. The reaction mixture 
rated with acetone/ether (1:1). The yellow solid was was concentrated to dryness to a dark orange oil which 
filtered, washed first with acetone/ether (1:1), then was triturated with cold acetone to yield a bright yel-
with ether and dried to yield 3.57 g (97%) of pure prod- low precipitate that was washed with acetone and 
uct, m.p. 183°-184° C. (dee.). IH NMR (d6-DMSO) B: ether. After drying the product weighed 4.02 g (92%). 
8.57 (d, IH, J =6.1 Hz); 8.50 (s, IH); 8.19 (d, IH, J = 8.2 IS 0-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyi)hydroxy-
Hz); 7.88 (d of d, IH, J = 6.1 Hz, J = 8.2 Hz); 7.38 (d, 2H, 1-methyl-2-pyridinemethylene] hydroxylamine chlo-
J = 8. 7 Hz); 6.95 (d, 2H, J = 8. 7 Hz); 5.25 (s, 2H); 4.26 (s, ride. The methiodide obtained in the previous step ( 4.02 
3H); 3. 75 (s, 3H). Anal. Cal ed. for C1sH17CIN203 X 0.55 g, 9 mmol) was dissolved in 25 mL HzO and 20 mL 
HzO: C, 6.53; H, 5.73; N, 8.79; Cl, 11.13. Found: C, acetonitrile. Freshly prepared AgCI (2.61 g, 18 mmol) 
56.53; H, 5.72; N, 8.79; Cl, 11.18. 20 was added to this solution and the resulting suspension 
O-(p-Dimethylaminocarbonyloxybenzyl)-N-(3- was stirred at room temperature for 1 h. The reaction 
hydroxy-1-methyl-2-pyridinemethylene) hydroxylam- mixture was filtered and the filtrate was concentrated to 
ine chloride, O-(p-propylaminocarbonylbenzyl)-N-(3- dryness to a white solid that was triturated with warm 
hydroxy-1-methyl-2-pyridinemethylene) hydroxylam- (40° C.) acetone for 20 min and filtered. The white solid 
ine chloride, and O-(p-ethoxycarbonylbenzyl)-N-(3- 25 was washed with acetone and ether to yield 3.2 g (quan-
hydroxy-1-methyl-2-pyridinemethylene) hydroxylam- titative) of the pure chloride, m.p. 150° -152° C. (dee.); 
ine chloride can be made by the same procedure replac- IH NMR (DMSO-d6) B: 9.09 (d, J = 5.5 Hz, lH); 8. 74 (s, 
ing 0-(p-methoxybenzyl) hydroxylamine in the above lH); 8.59 (d, J=8.4 Hz, lH); 8.19 (d of d, J=8.4 Hz, 
example respectively with 0-(p-dimethylaminocar- J=5.5 Hz, IH); 7.42 (m, 5H); 5.33 (s, 2H); 4.39 (s, 3H); 
bonyloxy benzyl) hydroxylamine, 0-(p- 30 2.98 (s, 3H); 2.92 (s, 3H). Anal. Calcd. for 
propylaminocarbonyl benzyl) hydroxylamine, and 0- C17H20CIN303X0.45 H10: C, 57.04; H, 5.89; N, 11.74; 
(p-ethoxycarbonyl benzyl) hydroxylamine. 0-(p- Cl, 9.91. Found: C, 56.99; H, 5.95; N, 11.69; Cl, 9.91. 
Methoxybenzyl)-N-( 5-hydroxy-1-methy 1-2- 0-Benzyl-N-[3-(N' ,N' -diethylcarbamoyl)hydroxy-1-
pyridinemethylene) hydroxylamine chloride, 0-(p- methyl-2-pyridinemethylene] hydroxylamine chloride 
dimethylaminocarbonyloxy benzyl)-N-(5-hydroxy-1- 35 and O-benzyl-N-[3-(N',N'-difluoroethylcarbamoyl)hy-
methyl-2-pyridinemethy Jene) hydroxylamine chloride, droxy-1-methyl-2-pyridinemethylene] hydroxylamine 
0-(p-propylaminocarbonyl benzyl)-N-(5-hydroxy-1- chloride can be made by the same procedure repiacing 
methyl-2-pyridinemethylene) hydroxylamine chloride, N,N-dimethylcarbamoyl chloride respectively with 
and O-(p-ethoxycarbonylbenzyl)-N-(5-hydroxy-1- N,N-diethylcarbamoyl chloride and N,N-difluoroethyl-
methyl-2-pyridinemethylene) hydroxylamne chloride 40 carbamoyl chloride. 0-Benzyl-N-[5-(N',N'-dimethyl-
can be made by the same procedure replacing 3- carbamoyl) hydroxy-1-methyl-2-pyridinemethylene] 
hydroxy-2-pyridine aldehyde in the above example with hydroxylamine chloride, O-benzyl-N-[5-(N',N'-diethyl-
2-formyl-5-hydroxy pyridine. carbamoyl)hydroxy-1-methyl-2-pyridinemethylene] 
EXAMPLE 6 
Preparation of 
0-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyl)hydroxy-1-
methyl-2-pyridinemethylene] hydroxylamine chloride 
(2a) 
hydroxylamine chloride and O-benzyl-N-[5-(N',N'-
45 difluoroethylcarbamoyl)hydroxy-1-methyl-2-
pyridinemethylene] hydroxylamine chloride can be 
made by the same procedure replacing 3-hydroxy-2-
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
0-Benzyl-N-[3-(N' ,N' -dimethylcarbamoyl)h ydroxy-
2-pyridinemethylene] hydroxylamine 
so 0-[2-(l-Methyl-1-piperidinium)ethyl]-N-[3-(N',N'-
dimethylcarbamoyl)hydroxy-1-methyl-2-
pyridinemethylene] hydroxylamine dichloride, and 0-
[2-(trimethylammonium)ethyl]-N-[3-N' ,N'-dimethyl-
carbamoyl)hydroxy-1-methyl-2-pyridinemethylene] Dimethylcarbamyl chloride (7 mL, 76 mmol) was added to a solution of 2.59 g (11 mmol) of O-benzyl-N-
(3-hydroxy-2-pyridinemethylene)hydroxylamine (pre- SS 
pared as reported on previous page) in 20 mL of pyri-
dine. The resulting mixture was stirred at 65° C. for 12 
h and poured over 400 mL of ice water. The aqueous 
solution was extracted with ether (6X50 mL); the ether 
layer was dried (Na2S04), filtered and concentrated to 60 
dryness to a yellow oil which was coevaporated with 
HzO and with acetone to remove the remaining pyri-
dine. The residue was dissolved in 10 mL acetone, and 
water was added with cooling and stirring until no more 
precipitate came out of solution. The white solid was 65 
filtered, washed with water and dried to yield 3.02 g 
(89%) of product; m.p. 65°-66° C. IH NMR (CDCl3) B: 
8.54 (d of d, lH, J =4Hz,J=1 Hz); 8.38 (s, lH); 7.54 (d 
hydroxylamine dichloride can be made by the same 
procedure replacing 0-benzylhydroxylamine in the 
above example with 0-[2-(l-piperidine)ethyl] hydroxy-
lamine and0-[2-(dimethylamino)ethyl] hydroxylamine. 
EXAMPLE 7 
Preparation of 
0-(Diphenylmethyl)-N-[3-(N' ,N' -dimethylcarbamoyl)-
hydroxy- l-methyl-2~pyridinemethylene] 
hydroxylamine chloride (2b) 
O-(Diphenylmethyl)-N-(3-hydroxy-2-
pyridinemethylene] hydroxylamine 
0-Diphenylmethyl hydroxylamine (3.4 g, 14.4 mmol; 
Grochowski et al, 1976 and Schumann et al, 1964, vide 
5,290,942 
27 
supra) was added to a solution of NaOH (0.58 g, 14.4 
mmol) in 7 mL of water. 3-Hydroxy-2-pyridine car-
28 
EXAMPLE 8 
baldehyde (1.8 g, 14.4 mmol) was added to this solution Preparation of 
and the resulting mixture was stirred at room tempera- 0-(p-Methoxybenzyl)-N-[3-(N',N'-dimethylcar-
ture for 4 h. The white solid in the reaction mixture was 5 bamoyl)hydroxy-1-methyl-2-pyridinemethylene] 
filtered, washed with H20/EtOH (1:1) and dried to hydroxylamine chloride (2c) 
yield 3.17 (72%) of product, m.p. 82°-83° C. 1H NMR 0-(p-Methoxybenzyl)-N-[3-(N',N'-dimethylcar-
(CDCIJ) o: 9.60 (s, lH); 8.51 (s, lH); 8.2 (d of d, lH); bamoyl)hydroxy-2-pyridinemethylene] hydroxylamine. 
7.30-7.43 (m, JOH); 7.23 (d of d, lH); 7.16 (d of d, lH); 10 Dimethylcarbamyl chloride (JO mL, 0.11 mo!) was 6.29 (s, lH). added to a solution of O-(p-methoxybenzyl)-N-(3-
O-(Diphenylmethyl)-N-(3-(N',N'-dimethylcarbamoyl)-
hydroxy-2-pyridinemethylene] hydroxylamine 
Dimethylcarbamyl chloride (9 mL, 98 mmol) was 15 
added to a solution of O-(diphenylmethyl)-N-(3-
hydroxy-2-pyridinemethylene) hydroxylamine (3.0 g, 
9.9 mmol) in 30 mL of pyridine. The resulting mixture 
was stirred at room temperature for 14 h and poured 
over 400 mL of crushed ice. A white solid precipitates 20 
upon scratching the sides of the beaker. It was filtered, 
washed thoroughly with water and dried to yield 3.47 g 
(94%) of product, m.p. 89°-90° C. IH NMR (d6-
DMSO) o: 8.49 (d of d, lH); 8.37 (s, lH); 7.64 (d of d, 
lH); 7.47 (d of d, lH); 7.42-7.28 (m, JOH); 6.29 (s, lH); 25 
2.81 (s, 3H); 2.74 (s, 3H). 
hydroxy-2-pyridinemethylene) hydroxylamine (3.3 g, 
12.8 mmol) in 30 mL of pyridine. The resulting mixture 
was stirred at room temperature for 14 h and then 
poured over 400 mL of crushed ice. Since it was not 
possible to induce precipitation of the product, the 
aqueous mixture was extracted with ether (4X 100 mL) 
and the organic extract was concentrated to dryness in 
vacuo. The oily residue was coevaporated with water 
to remove traces of pyridine and then with acetone. The 
300 MHz IH NMR of the resulting yellow oil shows no 
pyridine or water and was used in the next step without 
further purification. 
0-(p-Methoxybenzyl)-N-[3-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-methyl-2-pyridinemethylene] hy-
droxylamine chloride. Methyl iodide (2.9 mL, 46.4 
mmol) was added to each of two pressure glass tubes 
0-(Diphenylmethyl)-N-[3-(N',N'-dimethylcarbamoyl)- containing a solution of O-(p-methoxybenzyl)-N-[3-
hydroxy-1-methyl-2-pyridinemethylene] (N',N'-dimethylcarbamoyl)hydroxy-2-pyridinemethy-
hydroxylamine chloride 30 Jene] hydroxylamine (3.82 g, 11.6 mmol, divided into 
Methyl iodide (2.8 mL, 46 mmol) was added to a two) in 40 mL of acetonitrile. The sealed reaction ves-
solution of O-(diphenylmethyl)-N-(3-(N',N'-dimethyl- sels were heated at 70° C. for 3 days and then the sol-
carbamoyl)hydroxy-2-pyridinemethylene] hydroxy- vent was removed in vacuo. The resulting oil crystal-
lamine (3.44 g, 9.2 mmol) in 40 mL of acetonitrile. The lizes upon standing at 0°-5° C. for 14 h in a 2:1 mixture 
resulting mixture was divided into two pressure glass 35 of acetone/ether (75 mL). The yellow solid was fil-
vessels and heated at 70• c. for 3 days. The solvent was tered, washed with ether and dried to yield 4.94 g 
removed in vacuo and the residue (4.92 g) was dissolved (90%) of crude methiodide. It was dissolved in 1:1 mix-
in a mixture of acetonitrile/water (200 mL:200 mL). ture of H10/acetonitrile (200 mL) an? then freshly 
Freshly made AgCI (2 eq, washed well with H20) was made AgCJ (21 ~ol, wash~d well w1~h water) was 
added to this solution and the resulting suspension was 40 added. The resultmg suspension was stirred ~t room 
stirred at room temperature for 2 h. It was filtered temperature for 2 h and filtered thr~ugh Cehte. The 
through Celite and the filtrate was concentrated to filt~ate was co~centrated t.o dryness m vacuo and the 
dryness in vacuo to a residue that was triturated with rest.due ~as tnturated with 1:1 acetone/eth~r. The 
ether. The white solid was collected by filtration and white ~ohd th~t resulted was filtered, washed w.1th ether 
d · d t · Id 3 84 (98M) f d t 45 and dned to yield 3.72 g (84.4%) of pure chlonde, m.p. ne 0 yie · g -;o 0 pure pro uc ' m.p. 145° 6° C (.d ) A I C I d ti C H CIN 0 0 5 153°-154° C. (dee.). IH NMR (d6-DMSO) o: 9.06 (d, - · ec. · na · a c · or 18 22 3 4X · 
lH J -6 o H )· 8 87 ( lH)· 8 55 (d lH J= 8 4 H )· H20: C, 55.59; H, 5.96; N, J0.81; CJ, 9.12. Found: C, 
' - . z' . S, ' . ' ' • z' 55.59; H, 6.03; N, J0.76; Cl, 9.17. 
8.18 (d of d, lH, J=6.0 Hz, J=8.4 Hz); 7.45-7.30 (m, 0-(p-Methoxybenzyl)-N-[3-(N',N'-dimethylcar-
JOH); 6.44 (s, lH); 4.35 (s, 3H); 2.8 (s, 3H); 2.79 (s, 3H). 50 bamoyl)hydroxy-1-ethyl-2-pyridinemethylene] hydrox-
Anal. Calcd. for C23H24CIN303X 1.19 H20: C, 61.76; ylamine chloride, 0-(p-methoxybenzyl)-N-[3-(N',N'-
H, 5.94; N, 9.39; Cl, 7.93. Found: C, 61.76; H, 6.02; N, dimethylcarbamoyl)hydroxy-1-benzyl-2-
9.41; Cl? 7.97. , . pyridinemethylene] hydroxylamine bromide, O-(p-
O-(D1phenylmethyl)-~-p-(N -1sopropylcarbamoyl)- methoxybenzyl)-N-[3-(N',N'-dimethylcarbamoyl)hy-
?Ydroxy-l-~ethyl-2-pyndm.emethylene] hydroxyl~- ss droxy-1-(1-naphtylmethyl)-2-pyridinemethylene] hy-
me chlonde and 0-(dtphenylmethyl)-N-[3-(N -(2- droxylamine chloride, O-(p-methoxybenzyl)-N-[3-
flu~r~thyl)carbamoyl]hydroxy-1,-methyl-2~ (N' ,N' -dimethylcarbamoyl)hydroxy- J-(2-methyl-1-
pyndmemethylene] hydroxylamme. chlonde . can be naphtylmethyl)-2-pyridinemethylene] hydroxylamine 
made by the sa~e proced~re repl?c1~g N,N-du?ethyl- chloride, O-(p-methoxybenzyl)-N-(3-(N',N'-dimethyl-
carbamyl chlonde respectively with 1sopropyl 1socya- 60 carbamoyl)hydroxy-1-diphenylmethyl-2-
nate and 2-fluoroethyl isocyanate. 0-(Diphenylmethyl)- pyridinemethylene] hydroxylamine chloride, 0-(p-
N-[ 5-(N' -isopropylcarbamoyl)hydroxy-1-methyl-2- methoxybenzyl)-N-[3-(N' ,N' -dimethylcarbamoyl)hy-
pyridinemethylene] hydroxylamine chloride and 0-(di- droxy-1-(2-hydroxy-4-nitrobenzyl)-2-pyridinemethy-
phenylmethyl)-N-[5-(N'-(2-fluoroethyl)carbamoyl]hy- Jene] hydroxylamine chloride, O-(p-methoxybenzyl)-N-
droxy-1-methyl-2-pyridinemethylene] hydroxylamine 65 (3-(N' ,N' -dimethylcarbamoyl)hydroxy-1-(p-carbox-
chloride can be made by the same procedure replacing ybenzyl)-2-pyridinemethylene] hydroxylamine chlo-
3-hydroxy-2-pyridine aldehyde with 2-formyl-5- ride, and 0-(p-methoxybenzyl)-N-[3-(N',N'-dimethyl-
hydroxy pyridine. carbamoyl)hydroxy-1-(p-cyanobenzyl)-2-
29 
5,290,942 
30 
pyridineinethylene] hydroxylamine chloride can be 
made by the same procedure replacing methyl iodide in 
the above example respectively with ethyl iodide, ben-
zyl bromide, 1-chloromethyl naphtalene, l-chlorometh-
yl-2-methyl naphtalene, chlorodiphenylmethane, 2- S 
chloromethyl-4-nitrophenol, 4-chloromethyl benzoic 
acid, and 4-cyano benzyl chloride. 0-(p-Methoxyben-
zyl)-N-[5-(N' ,N' -dimethylcarbamoyl)hydroxy-l-meth-
yl-2-pyridinemethylene] hydroxylamine chloride, 0-(p-
methoxybenzyl)-N-[5-(N' ,N' -dimethylcarbamoyl)hy- 10 
8.35 (d, J = 2 Hz, lH); 7.58 (d, J = 9 Hz, lH); 7.35 (d of 
d, J =2 Hz, 9 Hz, lH). 
N-(5-Hydroxy-2-pyridinemethylene) hydroxylamine 
To 200 mL of 2.5% (w/w) sodium hydroxide solu-
tion was dissolved 5.5 g of 5-hydroxy-2-formylpyridine 
(45 mmol). Subsequently 12.5 g of hydroxylamine HCI 
(180 mmol) was added to the solution in one portion. 
The solution turned cloudy after being stirred for 10 
minutes. After stirring at room temperature for 3 h, the 
precipitate was filtered under vacuum and dried in the droxy- l-ethyl-2-pyridinemethylene] hydroxylamine 
chloride, 0-(p-methoxybenzyl)-N-[ 5-(N' ,N'-dimethyl-
carbamoyl)hydroxy- l-benzyl-2-pyridinemethylene] hy-
droxylamine bromide, 0-(p-methoxybenzyl)-N-[5-
(N' ,N' -dimethylcarbamoyl)hydroxy- l-(l-naphtylme-
thyl)-2-pyridinemethylene] hydroxylamine chloride, 
0-(p-methoxybenzyl)-N-[ 5-(N' ,N' -dimethylcar-
bamoyl)hydroxy-1-(2-methyl- l-naphty lmethyl)-2-
pyridinemethylene] hydroxylamine chloride, 0-(p-
air for several days to yield 4.8 g of N-(5-hydroxy-2-
pyridinemethylene) hydroxylamine (78%). The solid is 
off white and decomposes at 195° C. 1H NMR (d6-
15 DMSO) 8: 11.27 (br, s, lH); 10.83 (br, s,.lH); 8.18 (d, 
J=2 Hz, lH); 8.05 (s, lH, CH=N); 7.72 (d, J=9 Hz, 
lH); 7.25 (d ofd, J=2 Hz, 9 Hz, lH). 
methoxybenzy 1)-N-[ 5-(N' ,N' -dimethylcarbamoyl)h y- 20 
droxy-l-diphenylmethyl-2-pyridinemethylene] hydrox-
ylamine chloride, 0-(p-methoxybenzyl)-N-[5-(N',N'-
dimethy lcarbamoyl)hydroxy-1-(2-hydroxy-4-nitroben-
zyl)-2-pyridinemethylene] hydroxylamine chloride, 0-
(p-methoxybenzyl)-N-[5-(N' ,N' -dimethylcarbamoyl)- 25 
hydroxy- l-(p-carboxybenzyl)-2-pyridinemethylene] hy-
droxylamine chloride, 0-(p-methoxybenzyl)-N-[5-
(N' ,N' -dimethylcarbamoyl)hydroxy-1-(p-cyanobenzyl)-
2-pyridinemethylene] hydroxylamine chloride can be 
made by the same procedure replacing 3-hydroxy-2- 30 
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
EXAMPLE 9 
Preparation of 
N-[5-(N' ,N' -Dimethylcarbamoyl)hydroxy- l-methyl-2- 35 
pyridine methylene] hydroxylamine chloride (2d) 
N-[ 5-(N' ,N' -Dimet_hylcarbamoyl)hydroxy-2-pyridine 
methylene] hydroxylamine 
Dimethylcarbamoyl chloride (5.2 mL, 57 mmol) was 
added to a solution of N-(5-hydroxy-2-pyridinemethy-
lene) hydroxylamine (6.53 g, 47 mmol) in 40 mL of 
pyridine. It was stirred at room temperature overnight 
and then the solvent was removed in vacuo, leaving a 
light green paste. The paste was dissolved in a minimum 
quantity of acetone and then triturated with ethyl ace-
tate and placed in the freezer overnight. Glassy needles 
formed and were filtered and washed with ethyl acetate 
to yield 3.0 g of pure product (30%), m.p. 134'-135' C. 
N-[5-(N' ,N' -Dimethylcarbamoyl)hydroxy- l-methyl-2-
pyridinemethylene] hydroxylamine chloride 
Methyl iodide (5.3 mL, 85 mmol) was added to a 
solution of N-[5-(N',N'-dimethylcarbamoyl)hydroxy-2-
pyridine methylene] hydroxylamine (2.8 g, 13.4 mmol) 
2-Formyl-5-hydroxypyridine in 25 mL of acetonitrile. The resulting mixture was put 
To a stirred solution of 21.8 g of 5-hydroxy-2-picoline into a glass pressure vessel and heated at 80' C. for 3 
(0.2 mo!) in 200 mL of glacial acetic acid was added 18 40 days. The solvent was removed in vacuo and the resi-
mL of 30% hydrogen peroxide (0.159 mo!) in one por- due was dissolved in a minimum quantity of acetone, 
tion. The mixture was heated in an oil bath at 80'-85' C. triturated with ether and placed in the freezer over-
with stirring for 3 h. Then another 18 mL of hydrogen night. A dark yellow solid resulted and was filtered 
peroxide was added and the mixture was stirred for 3 h under vacuum and washed with 1:1 ether/acetone to 
at the same temperature. Excess solvent was removed in 45 yield 3.25 g of the iodide salt. Freshly made AgCI (2 eq, 
vacuo followed by the addition of acetone, which washed well with water) was added to the iodide salt in 
caused the pyridine N-oxide to crystallize. Without acetonitrile/water (60 mL/100 mL) and stirred for sev-
further purification, 200 mL of acetic anhydride was era! hours. After filtration, the residue was crystallized 
added to the solid and the mixture was heated at 120' C. from acetone/ether and dried in the air for several days 
with stirring in an oil bath for 2 h. After cooling to room 50 to yield 2.5 g of the chloride salt (monohydrate, 72% 
temperature, excess acetic anhydride was removed ~y yield); m.p. 159'-160" c. IH NMR (d6-DMSO) 8: 9.18 
high vacuum distillation. The oily material was agam (s, lH); 8.65 (s, lH); 8.40 (d of d, 2H, J =2 Hz, 9 Hz); 
oxidized with 30% hydrogen peroxide twice and rear- 4.36 (s, 3H); 3.3 (s, HiO); 3.1 (s, 3H); 2.95 (s, 3H). Anal. 
ranged with acetic anhydride following the same proce- Calcd. for c 1ott14N3o3CI.H20: C, 43.25; H, 5.81; N, dure and amounts depicted above. The black oily mate- 55 15.13; Cl, 12.76. Found: c, 43.42; H, 5.81; N, 15.09; Cl, 
rial obtained was hydrolyzed with 200 mL of IN H<?I N-[3-(N',N'-Dimethylcarbamoyl)hydroxy-1-methyl-
(0.2 mo!) at room temperature for 3 weeks (hydr~l~s1s 2-pyridinemethylene] hydroxylamine chloride can be 
at higher tempe~ature may be ha~ful t~ the pyndme made by the same procedure replacing 2-formyl-5-
nucleus). The mixture was neutralized with anhydrous hydroxypyridine with 3-hydroxy-2-pyridine carbalde-
sodium carbonate, indicated by litmus paper and then 60 hyde. 
extracted three times with 300 mL of diethylether. The 
combined ether extracts were dried (MgS04), filtered 
and evaporated to leave a solid material in a small 
amount of oil. The pure product (7.8 g, 32%) was ob-
tained by filtering the solid, followed by washing it with 65 
a small amount of ether. It is yellow in color and shows 
a sharp melting point at 186'-187' C. IH NMR (d6-
DMSO) 8: 11.10 (br, s, lH, OH); 9.87 (s, lH, CHO); 
EXAMPLE 10 
Preparation of 
2-[[ (Aminocarbonyl)hydrazono ]methyl]-3-hydroxy- l-
methyl pyridinium chloride (3a) 
2-[[ (Aminocarbonyl)hydrazono ]methyl]-3-hydroxy 
pyridine 
5,290,942 
31 32 
trophenyl)-2-(5-hydroxy-1-methyl-2-pyridinemethy-
lene) hydrazine chloride, and 1-naphtyl-2-(5-hydroxy-1-
methyl-2-pyridinemethylene) hydrazine chloride can be 
made by the same procedure replacing 3-hydroxy-2-
Sodium acetate (2.21 g, 16 mmol) was dissolved in 25 
mL of water and then semicarbazide hydrochloride was 
added (1.81 g, 16 mmol), followed by 3-hydroxy-2-pyri-
dine aldehyde (2.0 g, 16 mmol). The resulting mixture 
was stirred at room temperature for 2 h. The solid in the 
reaction mixture was then filtered, washed with water 
and dried to yield 2.71 g (93%) of the semicarbazone. It 
was used in the next step without further purification; 
m.p.: 215°-217° C.(dec.). 
5 pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
2-Hydrazonomethyl-3-hydroxy-1,6-dimethyl pyridin-
ium chloride, 1-methyl-2-(1,6-dimethyl-3-hydroxy-2-
pyridinemethylene) hydrazine chloride, 1-methyl-1-
10 2-[[ (Aminocarbon yl)hydrazono ]meth yl]-3-hydroxy-1-
methyl pyrdinium iodide. 
A glass pressure tube containing a stirring bar was 
charged with 20 grams (11.1 mmoles) of 2-[[(aminocar-
bonyl)hydrazono]methyl]-3-hydroxy pyridine, 2.5 g of 15 
barium carbonate, 7.0 g (49.3 mmol) of methyl iodide 
and 30 mL of DMF. The reaction mixture was stirred 
for two days at 65° C. in an oil bath. After that time the 
solvent was removed in vacuo, the residue shaken with 
50 mL of warm water and filtered. The filtrate was then 20 
treated with an aqueous solution of H1S04 in amount 
needed for the precipitation of Ba2 + present in the solu-
tion. After collecting BaS04, the filtrate was concen-
trated and crystallized from a mixture of water and 
ethanol to afford 2.1 g (58.3%) of the methiodide salt, 25 
m.p. 180'-182° C. 
2-[[ (Aminocarbony l)hydrazono ]methy I]-3-hydroxy-1-
methy l pyridinium chloride 
phenyl-2-(1,6-dimethyl-3-hydroxy-2-pyridinemethy-
Jene) hydrazine chloride, and l,l-diphenyl-2-(1,6-
dimethyl-3-hydroxy-2-pyridinemethylene) hydrazine 
chloride can be made by the same procedure replacing 
3-hydroxy-2-pyridine aldehyde in the above example 
with 3-hydroxy-6-methyl-2-pyridine aldehyde. 
EXAMPLE 11 
Preparation of 
3-Hydroxy-1-methyl-2-[[ (N-phenylaminocarbonyl)hy-
drazono ]methyl] pyridinium chloride (3b) 
3-Hydroxy-2-[[(N-phenylaminocarbonyl)hydrazono]-
methyl] pyridine 
4-Phenyl semicarbazide (4.91 g, 33 mmol) was added 
to a suspension of 3-hydroxy-2-pyridine carbaldehyde 
( 4.0 g, 33 mmol) in a mixture of ethanol water (30 mL:40 
mL). The reaction mixture was stirred at room tempera-
ture for 3 h and the yellow product was collected by 
filtration. The yellow precipitate was washed with 
EtOH/H20 1:1 and dried under P20s to yield 8.22 g 
(99%) of product. It can be recrystallized from EtOH/-
H20; m.p. 201°-2° C. (dee.). IH NMR (d6·DMSO) 8: 
10.85 (br.s., lH); 10.6 (br.s., lH); 9.14 (s, lH); 8.27 (s, 
lH); 8.15 (d of d, lH); 7.55 (d, 2H); 7.26-7.36 (m, 4H); 
7.01 (t, lH). 
The preceeding iodide, 6.0 grams (18.6 mmol) was 30 
dissolved in 150 mL of water and stirred with silver 
chloride precipitated from a solution of 6.0 g (35.3 
mmol) of silver nitrate with excess of aqueous HC!. 
After 40 min the reaction mixture was filtered and the 
precipitate washed with a total of 100 mL of warm 35 
water. Pale yellow crystals of product melting at 3-Hydroxy-2-[[(N-phenylaminocarbonyl)hydrazono]-
2300-2320 C. (dee.) were obtained from the combined methyl]-1-methyl pyridinium chloride 
filtrate by both rotoevaporation and precipitation with Methyl iodide (7.2 mL, 0.12 mo!) was added to a 
acetone. Yield 4.12 grams (95.3%). IH NMR (D20, suspension of 2-[[(N-phenylaminocarbonyl) hy-
TSP) 8: 8.45 (s, lH), 8.36 (d, lH, J =5.8 Hz), 8.03 (d, 40 drazono]methyl]-3-hydroxy pyridine (3.72 g, 15 mmol) 
lH, J =8.3 Hz), 7.80 (d of d, lH), 4.42 (s, Me). Anal. in 50 mL of acetonitrile. The reaction mixture was 
Calcd for CsH11N402CI: C, 41.66; H, 4.81; N, 24.28; Cl, placed in two pressure glass vessels and heated at 70' C. 
15.37. Found C, 41.59, H, 4.85; N, 24.28; Cl, 15.44. for 3 days. The solid which filled the reaction flasks was 
2-[[(Aminothiocarbonyl)hydrazono]methyl]-3- filtered and triturated well with warm (40' C.) acetone. 
hydroxy-1-methyl pyridinium chloride, 2- 45 The product was dried to yield 5.13 g (89%) ofmethio-
hydrazonomethyl-3-hydroxy-1-methyl pyridinium dide. It was dissolved in a mixture ofwater/acetonitrile 
chloride, 1-methyl-2-(3-hydroxy-1-methyl-2- (500 mL:300 mL) and then freshly made AgCI (2 eq) 
pyridinemethylene) hydrazine chloride, 1-methyl-1- was added. The suspension was stirred at room temper-
phenyl-2-(3-hydroxy-1-methyl-2-pyridinemethylene) ature for 2 h and then filtered through Celite. The fil-
hydrazine chloride, l,l-diphenyl-2-(3-hydroxy-1-meth- 50 trate was concentrated to dryness in vacuo and the 
yl-2-pyridinemethylene) hydrazine chloride, 1-(2,4-dini- residue was triturated with acetone. The yellow solid 
trophenyl)-2-(3-hydroxy-1-methyl-2-pyridinemethy- was filtered, washed with acetone and dried to yield 
Jene) hydrazine chloride, and 1-(2-naphtyl)-2-(3- 3.67 g (93%) of the pure chloride; m.p. 220°-221° C. 
hydroxy-1-methyl-2-pyridinemethylene) hydrazine (dee.). It can be recrystallized from EtOH. IH NMR 
chloride can be made by the same procedure replacing 55 (d6·DMSO) 8: 11.74 (br.s., lH); 9.27 (s, lH); 8.58 (d, lH, 
semicarbazide in the above example respectively with J =5.7 Hz); 8.39 (s, lH); 8.17 (d, lH, J=8.2 Hz); 7.85 (d 
thiosemicarbazide, hydrazine, methylhydrazine, 1- of d, lH, J=5.7 Hz, J =8.2 Hz); 7.57 (d, 2H, J=7.6 Hz); 
methyl-1-phenylhydrazine, 1,1-diphenylhydrazine, 2,4- 7.31 (t, 2H, J=7.6 Hz); 7.04 (t, lH, J=7.6 Hz); 4.48 (s, 
dinitrophenylhydrazine, and 2-naphtylhydrazine. 2- 3H). Anal. Calcd. for C14ff1sClN402X0.95 H10: C, 
[[(Aminocarbonyl)hydrazono]methyl]-5-hydroxy-1- 60 51.90; H, 5.26; N, 17.29; Cl, 10.94. Found: C, 51.90; H, 
methyl pyridinium chloride, 2-[[(aminothiocarbonyl)- 5.22; N, 17.36; Cl, 10.89. 
hydrazono ]methyl]-5-hydroxy-1-methyl pyridinium 3-Hydroxy-1-methyl-2-[[ (N-phenylaminothiocar-
chloride, 2-hydrazonomethyl-5-hydroxy-1-methyl pyri- bonyl)hydrazono ]methyl] pyridinium chloride, 2-
dinium chloride, 1-methyl-2-(5-hydroxy-1-methyl-2- [[ (N,N-diphenylaminocarbonyl)hydrazono ]methyl]-3-
pyridinemethylene) hydrazine chloride, 1-methyl-1- 65 hydroxy-I-methyl pyridinium chloride, 2-[[(N,N-dime-
phenyl-2-(5-hydroxy-1-methyl-2-pyridinemethylene) thylaminothiocarbonyl)hydrazono ]methyl] 3-hydroxy-
hydrazine chloride, 1, 1-diphenyl-2-(5-hydroxy-1-meth- I-methyl pyridinium chloride, 2-[[(N-ethylaminothi-
yl-2-pyridinemethylene) hydrazine chloride, 1-(2,4-dini- ocarbonyl)hydrazono ]methyl]-3-hydroxy-1-methyl 
33 
5,290,942 
34 
EXAMPLE 13 
Preparation of 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N-dime-
thylcarbamoyl)hydroxy-l-methyl pyridinium chloride 
(4a) 
2-[[ (Aminocarbonyl)hydrazono ]methyl]-3-hydroxy 
pyridine 
pyridinium chloride, 3-hydroxy-l-methyl-2-[[(N-naph-
tylaminocarbonyl) hydrazono]methyl] pyridinium chlo-
ride, and 2-[[[N-(l-chloro-2-naphtyl)amino carbonyl]-
hydrazono ]methyl)-3-hydroxy- l-methy 1 pyridinium 
chloride can be made by the same procedure replacing 5 
4-phenylsemicarbazide in the above example respec-
tively with 4-phenyl-3-thiosemicarbazide, 4,4-diphenyl-
semicarbazide, 4,4-dimethyl-3-thiosemicarbazide, 4-
ethyl-3-thiosemicarbazide, 4-(2-naphtyl)semicarbazide 
and 4-(1-chloro-2-naphtyl)semicarbazide. S-Hydroxy-l- 10 Sodium acetate (2.21 g, 16 mmol) was dissolved in 25 
mL of water and then semicarbazide hydrochloride was 
methyl-2-[[(N-phenylaminocarbonyl)hydrazono] added (1.81 g, 16 mmol), followed by 3-hydroxy-2-pyri-
methyl] pyridinium chloride, 5-hydroxy-l-methyl-2- dine aldehyde (2.0 g, l6 mmol). The resulting mixture 
[[(N-phenylaminothiocarbonyl) hydrazono]methyl] was stirred at room temperature for 2 h. The solid in the 
pyridinium chloride, 2-[[(N,N-diphenylaminocar- 15 reaction mixture was then filtered, washed with water 
bonyl)hydrazono] methyl)-5-hydroxy-l-methyl pyri- and dried to yield 2.71 g (93%) of the semicarbazone. It 
dinium chloride, 2-[[(N,N-dimethylaminothiocarbonyl) was used in the next step without further purification; 
hydrazono]methyl)-5-hydroxy-l-methyl pyridinium m.p.:21s·-217• C.(dec.). 
chloride, 2-[[(N-ethylaminothiocarbonyl) hydrazono]-
methyl)-5-hydroxy-l-methyl pyridinium chloride, S~ 20 2-[[(Aminocarbonyl)hydrazono )methy~]-~-(N,N-dime-
hydroxy-l-methyl-2-[[(N-naphtylaminocarbonyl)hy- thylcarbamoyl)hydroxy pyndme 
drazono]methyl] pyridinium chloride, and 2-[[[N-(l- The semicarbazone obtained in the previous step 
chloro-2-naphtyl)amino carbonyl]hydrazono]methyl]- (2.71 g, 15 mmol) was suspended in 20 mL of pyridine 
5-hydroxy-1-methyl pyridinium chloride can be made and then N,N-dimethylcarbamyl chloride was added 
by the same procedure replacing 3-hydroxy-2-pyridine 25 (4.2 mL, 45 mmol). The reaction flask was sealed with 
aldehyde with 2-formyl-5-hydroxy pyridine. a septum and the mixture was stirred at room tempera-
EXAMPLE 12 ture for 20 h. The reaction mixture becomes a clear solution after one hour and the product begins to come 
out of solution after 2 h. When the reaction is complete, Preparation of 1-Methyl-2-[[(N-phenylaminocarbonyl) 
hydrazono]methyl] pyridinium chloride (3d) 
2-[[(N-Phenylaminocarbonyl) hydrazono]methyl] 
pyridine 
30 the mixture is cooled to 5°-10° C. in ice bath and fil-
tered. The beige solid that results is washed with aceto-
ne/ether 1:1 and dried to yield 3.63 g (96%) of the 
carbamate which is used in the next step without further 
Pyridine-2-Aldehyde (5. 7 mL, 0.06 mol) was added 
to a suspension of sodium acetate ( 4. 92 g, 0.06 mo!) and 35 
4-phenyl semicarbazide (9.07 g, 0.06 mol) in 60 mL of 
water. The resulting mixture was stirred at room tem-
perature for 14 hand the solid in suspension was filtered 
and washed thoroughly with water. After drying, the 
semicarbazone was obtained as a dark beige solid (12.54 40 
g, 87%) and was used in the next step without further 
purification; m.p. 18 l 0 -182° C. 
l-Methyl-2-[[(N-phenylaminocarbonyl) hydrazono]-
methyl] pyridinium chloride. 2-[[(N-Phenylaminocar-
bonyl) hydrazono]methyl) pyridine (4.47 g, 0.02 mol) 45 
was divided into two pressure glass tubes and dissolved 
in acetonitrile (20 mL each). Methyl iodide was then 
added (2.6 mL each, 0.04 mol), the tubes were tightly 
closed and heated at 65° C. for 3 days. The reaction 50 flasks were cooled to 10°-15° C. and the solid was fil-
tered. The yellow solid was washed with acetone and 
ether and dried to yield 6.66 g (92%) of the iodide salt; 
m.p. 192°-193° C. (dee.). It was dissolved in 400 mL of 
acetonitrile/water 1: 1 and exchanged with freshly made 55 
AgCI (from 5.92 g of AgN03 and excess cone. HCl, 
washed well with water). The resulting suspension was 
stirred at room temperature for 2 h. The silver iodide 
was filtered off and the filtrate was concentrated to 
dryness in vacuo to yield a yellow solid that was tritu- 60 
rated with acetone and ether. It was filtered and dried 
to yield 4.86 (96%) of the pure chloride salt as a yellow 
solid; m.p. 187°-188° c. (dee.). IH NMR (d6-DMSO) 8: 
11.87 (s, lH); 9.45 (s, lH); 8.98 (d of d, 2H); 8.56 (t, IH); 
8.43 (s, IH); 8.01 (t, lH); 7.62 (d, 2H); 7.34 (t, 2H); 7.08 65 
(t, IH); 4.36 (s, 3H). Anal. Calcd. for 
C1.Ji1sClN40X0.48 H20: C, 56.15; H, 5.37; N, 18.71; 
Cl, 11.84. Found: C, 56.15; H, 5.38; N; 18.69; Cl, 11.88. 
purification; m.p. 182°-3° C. (dee). 
2-[[(Aminocarbonyl)hydrazono]methyl)-3-(N,N-dime-
thylcarbamoyl)hydroxy-l-methyl pyridinium chloride 
The carbamate obtained in the previous step (3.63 g, 
14 mmol) was dissolved in SO mL hot (90° C.) DMF. 
When a clear solution was obtained, the reaction flask 
was cooled under running water until the inner temper-
ature reached 26' C. Methyl iodide (6.3 mL, 100 mmol) 
was then added and the reaction mixture was left at 65° 
C. in a Parr shaker for 3 days. The solvent was removed 
in vacuo to yield a dark viscous residue which was 
triturated with acetone. The yellow solid that resulted 
was washed with acetone/ether 1:1, then with ether and 
dried to yield 5.15 g (94%) of the methiodide. Freshly 
made AgCI (from 4.45 g AgN03 and excess cone. HCI) 
was washed well with water and added to a solution of 
the methiodide (5.15 g, 13 mmol) in 200 mL acetoni-
trile/water 1: 1. The resulting suspension was stirred at 
room temperature for 1.5 h. The silver iodide was fil-
tered through Celite and the filtrate was concentrated 
to dryness in vacuo to yield a residue which is triturated 
with acetone. The resulting solid is filtered and recrys-
tallized from CH3CN/EtOH and acetone to yield 2.44 g 
(62%) of the pure chloride salt; m.p. 194°-195° C. 
(dee.). Anal. Calcd. for C11H16ClN503X0.96 H20: C, 
41.42; H, 5.66; N,21.96; Cl, 11.12. Found: C, 41.42; H, 
5.72; N, 21.81; Cl, 11.20. 
2-[[(Aminocarbonyl)hydrazono]methyl]-3-(N,N-
dimethylcarbamoyl)hydroxy-l,6-dimethyl pyridinium 
chloride can be made by the same procedure replacing 
3-hydroxy-2-pyridine aldehyde in the above example 
with 3-hydroxy-6-methyl-2-pyridine aldehyde. 2-
[[(Aminocarbonyl)hydrazono ]methyl)-5-(N,N-dime-
thylcarbamoyl)hydroxy-1-methyl pyridinium chloride 
5,290,942 
35 
can be made by the same procedure replacing 3-
hydroxy-2-pyridine aldehyde in the above example with 
2-formyl-5-hydroxy pyridine. 
36 
trite. Methyl iodide was added to these solutions (1.2 
mL each, 0.02 mo!) and the resulting mixtures were 
heated at 70° C. for 3 days. The reaction mixtures were 
concentrated in vacuo to a dark residue which was EXAMPLE 14 
Preparation of 
3-(N,N-Dimethylcarbamoyl)hydroxy-1-methyl-2-[[(N-
phenylaminocarbonyl) hydrazono]methyl] pyridinium 
chloride (4b) 
5 triturated with acetone/ethanol 5:1. The resulting yel-
low solid was washed with acetone/ethanol 5:1 and 
dried to obtain 4.39 g (84%) of the iodide salt, m.p. 
193°-94° C. (dee). Freshly made AgCI (from 3.43 g of 
AgN03 and excess cone. HCI) was washed well with 
3-(N,N-Dimethylcarbamoyl)hydroxy-2-[[(N-
phenylaminocarbonyl)hydrazono] methyl] pyridine 
was prepared by reaction of dimethylcarbamyl chloride 
(16 mL, 0.18 mo!) with 3-hydroxy-2-[[(N-
phenylaminocarbonyl)hydrazono]methyl] pyridine (4.5 
10 water and added to a solution of the iodide salt ( 4.39 g, 
O.Ql mo!) in 300 mL acetonitrile/water 1: 1. The result-
ing suspension was stirred at room temperature for 2 h. 
The silver iodide was filtered through Celite and the 
g, 17.5 mmol) in 30 mL of pyridine. The resulting mix- 15 
ture was stirred at room temperature for 6 h and poured 
over 500 mL of crushed ice. The beige precipitate was 
collected, washed thoroughly with water and dried to 
yield 5.48 g (95%) of product, m.p. 178°-180° C. The 
product (5.48 g, 16.7 mmol) was dissolved in acetoni- 20 
trile/DMF and then methyl iodide (2. 78 mL, 44. 7 
mmol X 3 vessels) was added to the reaction vessel. The 
resulting mixture was stirred at 70° C. for 3 days and 
cooled in a water-ice bath for 30 min. The precipitate 
was collected by filtration, washed with acetone/ether 25 
1:1 and dried to yield 6.42 g (82%) of the methiodide 
salt. It was dissolved in 500 mL H20 and 300 mL aceto-
nitrile and then freshly made AgCl (2 eq, washed well 
with water) was added. The resulting suspension was 
stirred at room temperature for 2 h. It was filtered 30 
through Celite and the filtrate was concentrated to 
dryness in vacuo to a crisp yellow foam that becomes a 
yellow solid after trituration with acetone. The yellow 
solid was filtered, washed with ether and dried to yield 
4.83 g (93%) of pure product as the chloride salt; m.p. 35 
176°-177° C. (dee.). Anal. Calcd. for 
C17H20ClN503X0.84 H20: C, 51.95; H, 5.56; N, 17.82; 
Cl, 9.02. Found: C, 51.95; H, 5.55; N, 17.80; Cl, 9.11. 
5-(N ,N-Dimethylcarbamoyl)hydroxy-1-methy 1-2-
[[ (N-phenylaminocarbonyl) hydrazono]methyl] pyri- 40 
dinium chloride can be made by the same procedure 
replacing 3-hydroxy-2-pyridine aldehyde with 2-for-
myl-5-hydroxy pyridine. 
filtrate was concentrated to dryness in vacuo to yield a 
solid that was triturated with acetone. The dark beige 
solid was filtered, washed with acetone and dried to 
yield 2.89 g (84%) of pure product as the chloride salt; 
m.p. 230°-31° C. (dee.). Anal. Calcd. for 
C14li16ChN402x 0.96 H20: C, 46.65; H, 5.01; N, 15.55; 
Cl, 19.67. Found: C, 46.65; H, 4.95; N, 16.33; Cl, 20.66. 
2-(3-H ydroxy-1-methyl-2-pyridinemethylene )-1-[2-
(trimethylammonium)acety l] hydrazine dichloride, 1-
[2-( 4-chloro-1-pyridinium)acetyl]-2-(3-hydroxy-l-meth-
yl-2-pyridinemethylene) hydrazine dichloride, l-[2-(3-
carboxy-l-isoquinolinium)acetyl]-2-(3-hydroxy-1-meth-
yl-2-pyridinemethylene) hydrazine dichloride, 1-[2-(2-
carboxy-4-methoxy-1-quinolinium) acety 1]-2-(3-
hydroxy-1-methyl-2-pyridinemethylene) hydrazine di-
chloride, 2-(3-hydroxy-1-methy 1-2-pyridinemethy Jene)-
1-[2-(3-hydroxy-1-pyridinium)acetyl] hydrazine dichlo-
ride, 2-(3-hydroxy-1-methyl-2-pyridinemethylene)-1-[2-
(1-methyl- l-piperidinium) acetyl] hydrazine dichloride 
can be made by the same procedure replacing 1-(car-
boxymethyl) pyridinium chloride hydrazide respec-
tively with (carboxymethyl)trimethylammonium chlo-
ride hydrazide (Girard's reagent "T"), 4-chloro-1-(car-
boxymethyl)pyridinium chloride hydrazide, 3-carboxy-
1-(carboxymethyl)isoquinolinium chloride hydrazide, 
2-carboxy-4-methoxy-1-( carboxymethyl)quinolinium 
chloride hydrazide, 3-hydroxy-1-(carboxymethyl)-
pyridinium chloride hydrazide, and l-methyl-1-(carbox-
ymethyl) piperidinium chloride hydrazide. 2-(5-
Hydroxy-l-methyl-2-pyridinemethylene)-l-[2-(l-
pyridinium)acetyl] hydrazine dichloride, 2-{5-hydroxy-EXAMPLE 15 
Preparation of 
2-(3-Hydroxy- l-methy 1-2-pyridinemethylene )-1-[2-
(pyridinium)acetyl] hydrazine dichloride (5a) 
2-(3-Hydroxy-2-pyridinemethylene )-1-[2-( 1-pyridini-
um)acetyl] hydrazine chloride 
45 1-methyl-2-pyridinemethylene)-l-[2-(trimethylammoni-
um)acetyl] hydrazine dichloride, 1-[2-(4-chloro-1-
pyridinium)acetyl]-2-(5-hydroxy-1-methyl-2-
pyridinemethylene) hydrazine dichloride, 1-[2-(3-car-
boxy-1-isoquinolinium)acetyl]-2-(5-hydroxy-1-methyl-
1-(Carboxymethyl) pyridinium chloride hydrazide 
(2.63 g, 0.014 mo!) in IO mL of methanol was added to 
50 2-pyridinemethylene) hydrazine dichloride, l-[2-(2-car-
boxy-4-methoxy-1-quinolinium)acetyl]-2-( 5-hydroxy-1-
methyl-2-pyridinemethylene) hydrazine dichloride, 2-
(5-hydroxy-1-methyl-2-pyridinemethylene )-1-[2-(3-
a solution of 2-aldehyde-3-hydroxy pyridine (1.72 g, 
0.014 mol) in 20 mL of CH3CN. The resulting dark 55 
yellow solution is stirred at room temperature for 2 h 
and at the end of this period a beige solid filled the 
reaction mixture. Ethyl ether was added (10 mL) and 
the reaction mixture was cooled to 5°-10° C. before 
filtering the beige precipitate. The solid was washed 60 
with ethyl ether and dried to yield 3.72 g (91%) of 
product; m.p. 229°-30° C. (dee). 
2-(3-Hydroxy- l-methyl-2-pyridinemethylene )-1-[2-(l-
pyridinium)acetyl] hydrazine dichloride 65 
The acyl hydrazone obtained in the previous step (3.5 
g, 0.012 mo!) was divided into three pressure glass ves-
sels and each portion was dissolved in 20 mL of acetoni-
hydroxy- l-pyridinium)acetyl] hydrazine dichloride, 
and 2-(5-hydroxy- l-methyl-2-pyridinemethylene )-1-[2-
(1-piperidinium )acetyl] hydrazine dichloride can be 
made by the same procedure replacing 3-hydroxy-2-
pyridine aldehyde with 2-formyl-5-hydroxy pyridine. 
EXAMPLE 16 
Preparation of 
2-(1-Methyl-2-pyridinemethylene )-1-[2-( 1-pyridinium-
)acetyl] hydrazine dichloride (5b). 
2-(2-pyridinemethylene )-1-[2-( 1-pyridinium)acetyl] 
hydrazine chloride 
1-(Carboxymethyl) pyridinium chloride hydrazide 
(5.25 g, 28 mmol) and pyridine-2-carbaldehyde (2. 7 mL, 
37 
5,290,942 
38 
28 mmol) were dissolved in 2S mL acetonitrile:me-
thanol (4:1). The resulting mixture was stirred at room 
temperature for 2 h, with the product beginning to 
come out of solution after 20 min of reaction. After 2 h 
the white solid in the reaction mixture was filtered and 5 
washed with acetonitrile and ether. After drying, the 
product was obtained as a white solid (S.27 g, 68%) and 
was used in the next step without further purification; 
m.p. 240°-241° C.(dec.). IH NMR (d6-DMSO) 8: 12.43 
(br.s., lH); 9.07 (d, 2H); 8.70 (t, lH); 8.66 (d, lH); 8.24 10 
(d of d, 2H); 8.19 (s, lH); 8.01-7.90 (m, 2H); 7.48-7.44 
(m, lH); 6.07 (s, 2H). 
vacuo, and the residue was triturated with acetone to 
give the product as a shiny dark yellow solid (1.4 g, 
9S%), m.p. 163°-l6S° C. The chloride salt can be ob-
tained as described above. 
EXAMPLE 18 
Preparation of 
O-Benzyl-N-(l,6-dimethyl-3-hydroxy-2-pyridinemethy-
lene) Hydroxylamine Chloride 
3-Hydroxy-6-methyl-2-pyridine carbaldehyde 
3-Hydroxy-6-methyl-2-pyridine methanol (20.0 g, 
2-(1-Methyl-2-pyridinemethylene)-1-[2-(l-pyridinium- 0.14 mo!) and selenium dioxide(8.0 g, 72 mmol) were 
)acetyl] hydrazine dichloride dissolved in 140 mL of 1,4-dioxane and 280 mL of abso-
The acyl hydrazone obtained in the previous step 15 lute ethanol. The resulting mixture was heated at 
(2.88 g, 10 mmol) was divided into two pressure vessels 80°-8S° C. for 12 h. The selenium precipitate was re-
and each portion was dissolved in 25 mL of DMF. moved ~Y filtration and the filtrate.was concent~ated to 
Methyl iodide was added to these solutions (1.62 mL dryness m vacuo. The dark red residue was sublimed at 
each, 25 mmol) and the resulting mixtures were heated 20 90° C. and 14 mmHg for 6 h to obtain 11.0 g (S6%) of 
at 70° C. for 3 days. The solvent was removed in vacuo pure product, m.p. 101°-102° C.; 1H NMR (CDCb) 8: 
to yield a dark residue which was triturated with ace- 10.SO (br s, lH), 10.03 (s, lH), 7.27 (s, 2H): 2.53 (s, 3H). 
tone. The resulting solid was filtered, washed with ace-
tone and ether and dried to yield 4.2S g (quantitative) of 
the methiodide as a yellow solid. Freshly made AgCl 25 (from 3. 77 g AgN03 and excess cone. HCI) was washed 
well with water and added to a solution of the iodide 
salt ( 4.18 g, IO mmol) in 200 mL acetonitrile/water 1: 1. 
The resulting suspension was stirred at room tempera-
ture for 1.5 h. The silver iodide was filtered through 30 Celite and the filtrate was concentrated to dryness in 
vacuo to yield 3.63 g ofa yellow solid. Recrystallization 
from ethanol/acetone affords the pure chloride as a 
beige solid (3.0 g, 92%); m.p. 209°-210° C.(dec). IH 
NMR (d6-DMSO) o: 9.13 (d, 2H); 9.08 (d, lH); 35 8. 7S-8.S9 (m, 4H); 8.26 (t, 2H); 8.10 (m, lH); 6.19 (br.s., 
2H); 4.42 (s, 3H). Anal. Calcd. for C14H16CJiN40 x 0.91 
HiO: C, 48.94; H, 5.23; N, 16.31; Cl, 20.64. Found: C, 
48.94; H, S.2S; N, 16.31; Cl, 20.43. 
O-Benzyl-N-(3-hydroxy-6-methyl-2-pyridinemethy-
lene) hydroxylamine 
Sodium hydroxide (3.2 g, 0.08 mo!) was dissolved in 
80 mL of a 1: 1 mixture of ethanol/water and then 0-
Benzy lhydroxylamine hydrochloride (12.77 g, 0.08 
mo!) was added. The reaction mixture was stirred at 
room temperature and when a clear solution was ob-
tained 11.0 g (0.08 mo!) of 3-hydroxy-6-methyl-2-pyri-
dine carbaldehyde was added and the resulting mixture 
was stirred at room temperature for 11 h. The reaction 
mixture was cooled in an ice bath and filtered to yield 
18.S3 g (96%) of product as a white solid, m.p. 81°-82° 
C. IH NMR (Me2SO-d6) 8: 9.8S (br s, lH), 8.40 (s, lH), 
7.30-7.47 (m, SH), 7.22 (d, lH), 7.13 (d, lH), 5.22 (s, 
2H), 2.36 (s, 3H). 
EXAMPLE 17 
Preparation of 
40 O-Benzyl-N-(l,6-dimethyl-3-hydroxy-2-pyridinemethy-
lene) hydroxylamine iodide 
0-Dipheny Jmethyl-N-( 3-h ydrox y-1-methyl-2- O-Benzyl-N-(3-hydroxy-6-methy 1-2-pyridinemeth y-
pyridinemethylene) Hydroxylamine Iodide Jene) hydroxylamine (10.0 g, 0.04 mo!) was dissolved in 
O-Diphenylmet1~~~ft~ci;J~;~~;;~pyridinemethy- 45 i:d~~ ~~c~~~~!~~!e ~~~:;~ ~; ~~!;e:~~ :~~~!~~~ glass vessel at 90° C. for 3 days. The solvent was re-
0-Diphenyl methyl hydroxylamine hydrochloride moved in vacuo and the residue was triturated with 
(3.35 g, 14.2 mmol)_ was added to a solution of N~?H acetone to yield 8.1 g of a yellow solid. Recrystalliza-
(0.57 g, 14.2 mmol) m 10 mL ofH20. A~te~ the add1t1on tion from acetone/EtOH/EtiO yields S.S g (35%) of 
of 10 mL of EtOH, 3-hydroxy-2-pyndme aldehyde 50 pure product as a pale yellow solid IH NMR (Me2so-(l.7S g, 14.2 mmol) was add~d. The mi~ture was heated d6) o: 8.5S (s, lH); 7.92 (d, lH); 7.S7 (d, lH); 7.30-7.48 
on a steam bath. ~or 1 h. While the solution was allowed (m, SH); 5.2,S.33 (s, 2H); 3.93,4.08 (s, 3H); 2.72 (s, 3H). 
to cool an a?~1t10nal 30 mL of HiO was added: The O-Benzyl-N-(l,6-dimethyl-3-hydroxy-2-
product prec1p1t:ited out as yellow needles. The mtxture pyridinemethylene) hydroxylamine chloride. 0-Benzyl-
was filtered to isolate the pure product (3.8 g, 89%), 55 . . . 
m.p. 83°-84° c. IH NMR (CDCb) 8: 9_57 (s, lH); 8.40 N-(1,6-d~et~yl-.3-hydroxy-2-pyndmemethyl_ene) h~-(s, lH); 7.33 (s, lOH); 7.13 (m, 3H); 6.23 (s, lH). Anal. droxylamtne 1od1de (S.S g, 14 mmol) were dissolved m 
Calcd. for c 19H 16N2o 3: c, 74_97; H, 5.31; N, 9.21. 700 mL of water ~d 4.1 ~ (28 mmol) of freshly pre-
Found: c, 74.88; H, S.32; N, 9.17. pared AgCI (from silver rutra~e and exc~ss cone. HC~) 
60 was then added. The suspension was stirred mechan1-
O-Diphenylmethyl-N-(3-hydroxy-1-methyl-2-
pyridinemethylene) hydroxylamine iodide 
A solution of O-diphenylmethyl-N,(3-hydroxy-2-
pyridinemethylene) hydroxylamine (1.0 g, 3.29 mmol) 
in 4S mL of EtOH was placed in a glass pressure tube. 65 
Methyl iodide (0.9 mL, 13.8 mmol) was then added, and 
the tube was sealed tightly. The tube was heated at 69° 
C. in an oil bath for 20 h. The solvent was removed in 
cally for 2.S h at room temperature and the silver iodide 
was then removed by filtration. The filtrate was con-
centrated to dryness in vacuo and the residue was tritu-
rated with acetone to yield 3.6 g (86%) of pure product 
as a light beige solid, m.p. 17S 0 -6° C. (dee.). IH NMR 
(Me2SO-d6) 8: 8.S2, 8.06 (s, lH); 8.10 (d, lH); 7.8S (t, 
lH); 7.30-7.4S (m, SH); S.30, S.20 (s, 2H); 4.1, 3.9 (s, 
3H); 2.69 (s, 3H). Anal. Calcd. for C1sH11ClN202 x 0.15 
39 
5,290,942 
40 
H20: C, 60.96; H, 5.90; N, 9.48; Cl, 12.00. Found: C, temperature 3 h. The white precipitate was then filtered 
60.96; H, 5.90; N, 9.51; Cl, 12.02. and dried to yield 13.3 g (90%) of pure product, m.p. 
O-(l-Naphthylmethyl)-N-(l,6-dimethyl-3-hydroxy-2- 64•-65° C. IH NMR (CDCJ3) o: 9.72 (s, lH); 8.37 (s, pyridinemethylene) hydroxylamine chloride, 0-(2-
methyl-1-naphtylmethyl)-N-(1,6-dimethyl-3-hydroxy- 5 lH); 8.13 (d of d, J =2Hz, J =4Hz, lH); 7.33 (m, 7H); 
2-pyridinemethylene) hydroxylamine chloride, 0-meth- 5.17 (s, 2H). 
yl-N-(l,6-dimethyl-3-hydroxy-2-pyridinemethylene) O-Benzyl-N-(l-benzyl-3-hydroxy-2-pyridinemethy-
hydroxylamine chloride, O-(p-chlorobenzyl)-N-(1,6- lene) hydroxylamine bromide. Benzyl bromide (0.78 
dimethyl-3-hydroxy-2-pyridinemethylene) hydroxy- mL, 6.6 mmol) was added to a solution of 0-benzyl-N-
lamine chloride, O-(p-cyanobenzyl)-N-(l,6-dimethyl-3- 10 (3-hydroxy-2-pyridine methylene) hydroxylamine (1.0 
h.ydroxy-2-pyridinemeth~lene) hydroxylam~e chlo- g, 4.4 mmol) in 4 mL of acetonitrile. The resulting mix-
nde, 0-(2-hydroxy-4-rutrobenzyl)-N-(l,6-d1methyl-3- ture was heated at 65• C. in a pressure bottle for 3 days. 
hydroxy-2-pyridinemethylene) hydroxylamine chlo- . 
'd o (p th b l) N (l 6 d' h 1 3 h d The solvent was removed m vacuo and coevaporated n e, - -me oxy enzy - - , - 1met y - - y roxy- . . . . . 
2-pyridinemethylene) hydroxylamine chloride, O-(p- 15 with water to leave an oily res1d~e that :was dissolved m 
dimethyl aminocarbonyloxybenzyl)-N-(l,6-dimethyl-3- 100 mL of water and treated with activated charcoal. 
hydroxy-2-pyridinemethylene) hydroxylamine chlo- This mixture was filtered through Celite and the filtrate 
ride, 0-(p-propylaminocarbonyl benzyl)-N-(1,6- was concentrated to dryness under high vacuum. Ace-
dimethyl-3-hydroxy-2-pyridine methylene) hydroxy- tone (20 mL) was added to the residue and the product 
!amine chloride, 0-benzyl-N-[3-(N',N'-dimethylcar- 20 crystallized as light beige needles (1.5 g, 86%), m.p. 
bamoyl)hydroxy-1,6-dimethyl-2-pyridinemethylene] 145°-146° c. IH NMR (CDCb) o: 8.68 (s IH)· 8.63 (d 
hydroxylamine chloride, ~-benzyl-N-[~-(~',N'-diethyl- of d, lH); 8.52 (t, lH); 7.69 (d of d, lH); 7.35 (m, 8H); carbamoyl)~ydroxy-l,6-~1methyl-2-pyndmemethylene] 7 10 ( 2H)· 6 12 ( 2H)· 5 25 ( 2H) A I c I d ~ hydroxylamme chlonde, 0-benzyl-N-[3-(N',N'- · m, • · s, • · s, · na · a c · or 
difluoroethylcarbamoyl)hydroxy-1,6-dimethyl-2- 25 C20H19BrN202: C, 60.16; H, 4.80; N, 7.02; Br, 20.02. pyridinemethylene] hydroxylamine chloride, 0-(di- Found: C, 59.89; H, 4.86; N, 7.00; Br, 19.91. 
phenylmethyl)-N-[3-(N',N'-dimethylcarbamoyl)hy- O-Benzyl-N-(l-benzyl-5-hydroxy-2-pyridinemethy-
droxy-1,6-dimethyl-2-pyridinemethylene] hydroxylam- lene) hydroxylamine bromide can be made by the same 
ine chloride, O-(diphenylmethyl)-N-[l,6-dimethyl-3- procedure replacing 3-hydroxy-2-pyridine aldehyde in 
(N'-isopropylcarbamoyl)hydroxy-2-pyridinemethy- 30 the above example with 2-formyl-5-hydroxy pyridine. 
Jene] hydroxylamine chloride, 0-(diphenylmethyl)-N-
[3-[N' -(2-fluoroethyl)carbamoyl)hydroxy-1,6-dimethy 1-
2-pyridinemeth ylene] hydroxylamine chloride, 0-(p-
methoxybenzyl)-N-[3-(N',N'-dimethylcarbamoyl)hy-
droxy-l,6-dimethyl-2-pyridinemethylene] hydroxylam- 35 ine chloride, 0-(p-methoxybenzyl)-N-[3-(N' ,N'-dime-
thylcarbamoy l)hydroxy-1-ethyl-6-methy 1-2-
pyridinemethy lene] hydroxylamine chloride, 0-(p-
methoxybenzyl)-N-[3-(N' ,N' -dimethylcarbamoyl)hy-
droxy-l-benzyl-6-methyl-2-pyridinemethylene] hydrox- 40 ylamine bromide, N-[3-(N',N'-dimethylcarbamoyl)hy-
droxy-I, 6-dimethyl-2-pyridinemethylene] hydroxylam-
ine chloride, 1,6-dimethyl-3-hydroxy-2-[[(N-
phenylaminocarbonyl)hydrazono] methyl] pyridinium 
chloride, l,6-dimethyl-3-hydroxy-2-[[(N-phenylamino- 45 
thiocarbonyl) hydrazono]methyl) pyridinium chloride, 
l,6-Dimethyl-2-[[(N,N-diphenylaminocarbonyl) hy-
drazono]methyl)-3-hydroxy pyridinium chloride, 2-
(1,6-dimethyl-3-hydroxy-2-pyridinemethylene)-1-[2-(l-
pyridinium)acetyl] hydrazine dichloride, 2-(1,6-dimeth- 50 yl-3-hydroxy-2-pyridinemethylene )-1-[2-(trimethylam-
monium)acetyl] hydrazine dichloride, and 2-(1,6-
dimethyl-3-hydroxy-2-pyridinemethylene )-1-[2-( 4-
chloro-1-pyridinium)acetyl] hydrazine dichloride can 
be made by the same procedure replacing 3-hydroxy-2- 55 pyridine carbaldehyde with 3-hydroxy-6-methyl-2-pyri-
dine carbaldehyde. 
EXAMPLE 19 
Preparation of 60 O-Benzyl-N-(l-benzyl-3-hydroxy-2-pyridinemethy-
Jene) hydroxylamine bromide 
O-Benzyl-N-(3-hydroxy-2-pyridinemethylene) hy-
droxylamine. 0-Benzyl hydroxylamine (10.4 g, 65 
mmol) was added to a solution of NaOH (2.6 g, 65 65 
mmol) in 66 mL of H20/EtOH 1 :1. 3-Hydroxy-2-pyri-
dine carbaldehyde (8.0 g, 65 mmol) was added to this 
solution and the resulting mixture was stirred at room 
TABLE I 
Kinetic Constants for the Reversible Inhibition of 
Electric Eel and Human Erythrocyte Acetylcholinesterase. 
com pd 
la 
lb 
le 
Id 
le 
If 
3a 
3b 
4b 
Sa 
Sb 
K1 (eel) K1 (human) ICso (eel) ICso (human) 
µM µM µM µM 
40 
500 
30, 34()1> 
85 
JO 
100 
100 
20 
100 
NJD 
400 
400 
NJD 
325 
40 
175 
NJD 
>500 
>500 
NI0 
300 
240 
40 
°NI, no inhibition at concentrations up to l mM. 
"rwo distinct K/s with eel AChE, multiple binding with both enzymes. 
'Multiple binding observed, only ICso values determined. 
TABLE II 
Kinetic Constants for the Irreversible Inhibition of 
Electric Eel and Human Erythrocyte Acetylcholinesterase. 
com pd 
2a 
2b 
2c 
4a 
Pyrb 
Ph yd 
1700 
870 
5000 
25 
S80C 
14000" 
68000 
1100 
>110000 
2200 
13000 
19000 
K1(eel) 
(µM) 
NT" 
NT" 
"NT, not tested (inhibition half·life is too short to measure accurately); 
bpyridostigmine; 
'kow'[IJ = 843 M- 1,-1 (Fonberg, A. and Puu, G., Eur. J. Biochem. 1984, 140, 
IS3.); 
oPh ysostigmine; 
'kow'[IJ = 18SOO M- 1,-1 (Forsberg. A. and Puu, G., Eur. J. Biochem. 1984, 140, 
IS3.). 
41 
TABLE III 
5,290,942 
42 
In Vivo Evaluation of Pyridinium Derivatives as Intramuscular 
Pretreatment Agents Against GD in Mice. 
LDso time• doscb % 
com pd (µmol/kg) (min) (µmol/kg) survival 
la 180 IS/60 3.0--4.S 10-20 
lb >880 IS/60 22 0/10 
Id >320 15/60 9.6 10/20 
le >760 IS/60 320/81 40/10 
If >610 IS/60 310/77 30/20 
lg >514 15/60 16/260 10/20 
2a o.s IS/60 0.009-0.14 80-90 
2b 22 IS 0.30 90 
1.4 60 
S.4 30 
60 0.30-S.4 60-70 
2c 84 IS/60 0.00S-0.11 S0-70 
2d 600 IS/60 9.0 90190 
37 90/70 
150 SO/O 
3b >40 IS/60 1.3/5.2 0/20 
3c >560 IS/60 0.017-0.28 40-70/30-40 
3d >430 15/60 0.013-0.215 20-40/10-30 
4a >1240 15/60 0.2 S0/90 
0.6 80/100 
2.3 80/80 
4b 42 15 0.65 90 
2.7 90 
II 40 
4b 60 0.65-11 70-80 
5a >670 15/60 18-290 70-100/20-70 
Sb 380 IS/60 0.6 40/20 
24 100/30 
96 100/100 
5 
10 
15 
20 
25 
TABLE V-continued 
In Vivo Evaluation of Pyridinium Derivatives as 
Reactivators Against GD in Mice. 
LDso dose• % 
com pd (µmol/kg) (µmol/kg) survival 
3b >40 1.3 10 
3c >S60 0.28 10 
3d >430 0.21S 20 
4a 9.6 0.2-2.3 0-50 
4b 42 0.65-11 30-50 
Sa >670 18-290 70-90 
Sb 380 6 20 
24 40 
96 90 
2-PAMCI 853 S3 0 
HI-6 4500 280-1125 90-100 
°Three different doses were tested, onJy one dose is recorded for inactive com-
~unds; 
Adjunct efficacy test, see text for details. 
TABLE VI 
In Vivo Evaluation of Pyridinium Derivatives as Reactivators 
Against GA in Mice. 
LDso dose % 
com pd (µmol/kg) (µmol/kg) survival• 
le >1970 30 0 
If 2100 33 0 
lg >510 16 0 
2a 0.5 0.009 30 
2c 84 0.005 20 
4a 9.6 0.60 20 
4b 670 2.70 30 
"Compounds were tested at two different time intervals to allow for differences in 30 
bioavailability; 
Sa >670 18 10 
73 80 
~rec different doses were tested, onJy one dose is recorded for inactive com-
pounds. Sb 380 
290 90 
6 10 
24 0 
96 80 
__________ T_A_B_L_E _ IV __________ 35 "Three different doses were tested, only one dose is recorded for inactive com· 
In Vivo Evaluation of Pyridinium Derivatives as Oral 
Pretreatment Agents Against GD in Mice. 
LDso time• doseb % 
com pd (µ.mol/kg) (min) (µmol/kg) survival 
lb 3600 30/120 60 30/70 
le >3200 30/120 200 0/50 
2a 220 30/120 3.4 90/80 
2b 490 30/120 120 90/100 
2c 140 30/120 2.2 100/100 
4b 670 30/120 10 70/100 
Sa 2900 30/120 730 40/SO 
"Compounds were tested at two different time intervals to allow for differences in 
bioavailability; 
'Three different doses were tested, only one dose is recorded for inactive com-
pounds. 
TABLE V 
pounds. 
What is claimed is: 
1. A compound of the group consisting of the formu-
40 las: 
xn andnx 
N CH=NOR1 B N CH=NOR1 
I+ I+ 
z z 
with any counterion to make pharmaceutically accept-
50 able salts, wherein 
--------------------- Z is selected from the group consisting of C1-6 alkyl, In Vivo Evaluation of Pyridinium Derivatives as 
Reactivators Against GD in Mice. 
LDso dose0 
corn pd (µmol/kg) (µmol/kg) 
la 180 2.8 
lb >880 S.6 
Id >320 40 
le >760 20 
If >610 12 
lg >514 IS 
2a o.s 0.009-0.14 
2b 22 0.33 
1.4 
S.4 
2c 84 1.3 
3a >1100 21b 
11ob 
43ob 
6.8 
S4 
430 
% 
survival 
20 
20 
20 
0 
0 
0 
30-SO 
20 
70 
60 
20 
so 
70 
90 
20 
0 
70 
C1-6alkyl with an attached phenyl group, C1-6alkyl 
with an attached naphthyl group, C1-6 alkyl with 
two attached phenyl groups, Ct-6 alkyl with an 
55 attached phenyl group mono, di, or trisubstituted 
with J, C1-6alkyl with two attached phenyl groups 
mono, di, or trisubstituted with J, C1-6 alkyl with an 
attached naphthyl group mono, di, or trisubstituted 
with J, 
60 wherein i is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, Ct-6 alkyl, 
Ct-6 alkoxy, Ct-6 alkylamine, Ct-6 al-
kyl-Q-CO-, Ct-6 alkyl-0-CO-NH-, C1.6 
alkyl-NH-CO-NH-, C1-6 alkyl-N-
65 H-C0-0-, C1-6 alkyl NH-CO-, (Ct-6 alkyl)-
2N-CO-, 
wherein X is selected from the group consisting of 
OH, C1-6 alkyl-NH-C0-0-, (C1.6 alkyl)-
43 
5,290,942 
44 
2-N-CO-O-, 
H-C0-0-, 
H-C0-0-, 
fluoroalkyl-N-
fluoroalkyl)2-N-
wherein R1 is selected from the group consisting of 
Ci-6 alkyl, C1-6 alkyl with an attached phenyl 5 
group, C1-6alkyl with two attached phenyl groups, 
C1.6 alkyl with an attached phenyl group mono, di, 
or trisubstituted with K, C1-6 alkyl with two at-
tached phenyl groups mono, di, or trisubstituted 
with K, C1-6 alkyl with an attached naphthyl 10 
group, C1-6 alkyl with an attached naphthyl group 
mono, di, or trisubstituted with K, C1-6 alkyl-T, 
wherein T is selected from the group consisting of 
formula (I) and formula (II), 
R' Formula I 
I 
-N+-R" 
I 
R"' 
Formula II 
15 
20 
25 
wherein R', R", and R"' are selected from the group 
consisting of H, C1-6 alkyl, C1-6 fluoroalkyl, C1-6 
alkyl with an attached phenyl group, C1-6 alkyl 
with an attached phenyl group mono, di, or trisub-
stituted with K, C1.6 fluoroalkyl with an attached 30 
phenyl group mono, di, or trisubstituted with K, 
wherein K is selected from the group consisting of 
halogen, COOH, OH, CN, N02, NH2, C1-6 alkyl, 
C1-6 alkoxy, C1.6 alkylamine, C1-6 al-
kyl-0-CO-, C1.6 alkyl-0-CO-NH-, C1-6 35 
alkyl-NH-CO-NH-, C1.6 alkyl-N-
H-C0-0-, C1.6 alkyl NH-CO-, (C1-6 alkyl)-
2N-CO-, 
wherein Bis selected from the group consisting of H, 
C1.6 alkyl. 40 
2. A compound of the group consisting of the formu-
las: 
xll 
""N+ I CH=NOH 
I 
lJ:x 45 
and B "" N+ 
1 
CH=NOH 
z 
I 
z 
so 
with any counterion to make pharmaceutically accept-
able salts, wherein 
Z is selected from the group consisting of C1-6filkyl, 
C1.6alkyl with an attached phenyl group, C1.6filkyl 
with an attached naphthyl group, C1.~lkyl with 55 
two attached phenyl groups, C1-6alkyl with an 
attached phenyl group mono, di, or trisubstituted 
with J, C1.6filkyl with two attached phenyl groups 
mono, di, or trisubstituted with J, C1.6alkyl with an 
60 
65 
attached naphthyl group mono, di, or trisubstituted 
with J, 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, C1.~lkyl, C1.6filk-
oxy, C1-~lkylamine, C1.6filkyl-O-CO-, C1.6 
alkyl-0-CO-NH-, C1-6 alkyl-N-
H-CO-NH-, C1-~lkyl-NH-CO-O-, C1. 
6alkyl NH-CO-, (C1-~lkyl)2N-CO-, 
X is selected from the group consisting of OH, C1. 
6alkyl-NH-C0-0-, (C1.6filkyl)-
2-N-CO-O-, C1-6fluoroalkyl-N-
H-CO-O-, (C1.6fluoroalkyl)2-N-
H-CO-O-, and 
B is selected from the group consisting of H, C1.~l­
kyl. 
3. A compound of the formula: 
(1 
N+ CH=NOR9 
I 
z 
with any counterion to make pharmaceutically accept-
able salts, wherein 
Z is selected from the group consisting of C1.~lkyl, 
C1.6filkyl with an attached phenyl group, C1-~lkyl 
with an attached naphthyl group, C1.~lkyl with 
two attached phenyl groups, C1-~lkyl with an 
attached phenyl group mono, di, or trisubstituted 
with J, C1.~lkyl with two attached phenyl groups 
mono, di, or trisubstituted with J, C1.6filkyl with an 
attached naphthyl group mono, di, or trisubstituted 
with J, 
J is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, C1.~lkyl, C1-6alk-
oxy, C1.~lkylamine, C1.~lkyl-O-CO-, C1. 
6alkyl-O-CO-NH-, C1.6filkyl-N-
H-CO-NH-, C1-~lkyl-NH-CO-O-, C1. 
6alkyl NH-CO-, (C1-~lkyl)2N-CO-, 
R9 is selected from the group consisting of C1.~lkyl 
with an attached phenyl group, C1-6alkyl with two 
attached phenyl groups, C1.~lkyl with an attached 
phenyl group mono, di, or trisubstituted with K, 
C1.6filkyl with two attached phenyl groups mono, 
di, or trisubstituted with K, C1~lkyl with an at-
tached naphthyl group, C1-6filkyl with an attached 
naphthyl group mono, di, or trisubstituted with K, 
and 
K is selected from the group consisting of halogen, 
COOH, OH, CN, N02, NH2, C1-6 alkyl, C1-6alk-
oxy, C1-6alkylamine, C1-6alkyl-O-CO-, C1. 
6alkyl-O-CO-NH-, C1-6alkyl-N-
H-CO-NH-, C1-6alkyl-NH-CO-O-, C1. 
6alkyl-NH-CO-, (C1-6alkyl)2N-CO-. 
• • • • • 
